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1 Zusammenfassung 
1.1 Hintergrund 
Der Adenosindiphosphat-Rezeptor P2Y12 bewirkt Plättchenaggregation und trägt zur Bildung 
arterieller Thrombosen bei. P2Y12-Antagonisten, wie Clopidogrel und Ticagrelor, werden 
daher zur Prävention von Herzinfarkten und Schlaganfällen in Patienten mit einem akuten 
Koronarsyndrom (AKS) verwendet. Ticagrelor war Clopidogrel in der Reduktion der Mortalität 
in diesen Patienten überlegen und die zugrunde liegenden Mechanismen sind nicht 
vollständig geklärt. Die arterielle Thrombose ist das zentrale Ereignis in der Entwicklung des 
AKS und das Gefässendothel ist wesentlich an dessen Entstehung beteiligt. Mögliche Effekte 
von P2Y12-Antagonisten auf das Endothel und seinen prokoagulatorischen Faktoren, 
insbesondere dem Gewebefaktor, wurden bisher nicht untersucht. Patienten mit AKS haben 
häufig Komorbiditäten wie Vorhofflimmern (VHF) und benötigen daher eine zusätzliche 
antikoagulatorische Therapie zum Schutz vor Embolien kardialer Thromben aus dem linken 
Herzohr. Ähnlich dem Endothel, führt eine Aktivierung des Endokards zu einer 
Überexpression des Gewebefaktors sowie des Plasminogenaktivator-inhibitors-1, welche zur 
Thrombogenität in Patienten mit Vorhofflimmern beitragen. Ob bestimmte P2Y12-
Antagonisten antithrombotische Eigenschaften auf das Endokard linker Herzohren aufweisen 
und dadurch die Thrombogenität in Patienten mit VHF reduzieren könnten, wurde bisher 
nicht untersucht. 
 
1.2 Material und Methoden 
Menschliche aortale Endothelzellen wurden mit Ticagrelor oder mit dem aktiven Metaboliten 
von Clopidogrel behandelt und mit Tumor-Nekrose-Faktor-alpha (TNF-α) stimuliert. 
Anschliessend wurden die Expression und Aktivität des Gewebefaktors sowie die zugrunde 
liegenden molekularen Mechanismen erforscht. Zusätzlich wurden C57BL/6 Mäuse mit 
Ticagrelor oder Clopidogrel behandelt und die Expression des endothelialen Gewebefaktors 
sowie die Bildung arterieller Thrombosen nach photochemische Schädigung des Endothels 
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der Halsschlagadern untersucht. Schliesslich gewannen wir Endokardzellen aus linken 
Herzohren von 14 Patienten mit VHF, welche sich einer elektiven Herzoperation unterzogen. 
Diese wurden mit Ticagrelor oder mit dem aktiven Metaboliten von Clipidogrel behandelt und 
mit TNF-α stimuliert bevor die Expression und Aktivität des Gewebefaktors und des 
Plasminogenaktivator-inhibitors-1 analysiert wurden. 
 
1.3 Ergebnisse 
Ticagrelor, im Gegensatz zum aktiven Metaboliten von Clopidogrel, verringerte die TNF-α-
induzierte Expression und Aktivität des Gewebefaktors durch proteasomale Degradierung  
unter Einbezug der Signalmoleküle Phosphoinositide-3-Kinase und p70s6 Kinase und 
unabhängig vom P2Y12 Rezeptor sowie dem equilibrative nucleoside transporter 1 (ENT1). 
Wie in unseren in vitro Experimenten, reduzierte Ticagrelor, nicht aber Clopidogrel, die 
Expression des endothelialen Gewebefaktors in Mausarterien und verlängerte die Zeit bis zur 
Entstehung arterieller Thrombosen. Dabei waren die Plättchenhemmung, die 
Gewebefaktoraktivität im Plasma und die systemische Koagulation in beiden Gruppen 
vergleichbar. In Endokardzellen linker Herzohren von Patienten mit Vorhofflimmern 
verminderte Ticagrelor, nicht aber Clopidogrel, die TNF-α-induzierte Expression und Aktivität 
des Gewebefaktors und des Plasminogenaktivator-inhibitors-1.  
 
1.4 Konklusionen 
Ticagrelor, nicht aber Clopidogrel, weist lokale antithrombotische Eigenschaften auf das 
Endothel auf und reduziert die Entstehung von arteriellen Thrombosen im Vergleich zu 
Clopidogrel. Zudem zeigt Ticagrelor, nicht aber Clopidogrel, lokale antithrombotische Effekte 
im Endokard linker Herzohren von Patienten mit VHF auf. Die antithrombotischen 
Eigenschaften von Ticagrelor tragen möglicherweise zur Reduktion der Mortalität von 
Patienten mit AKS in klinischen Studien bei und vermindern allenfalls das Risiko für 
systemische Thromboembolien in Patienten mit Vorhofflimmern.  
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2 Summary 
2.1 Background 
The adenosine diphosphate receptor P2Y12 mediates platelet aggregation and contributes to 
arterial thrombus formation; therefore, P2Y12 antagonists, such as clopidogrel and ticagrelor, 
are used to prevent myocardial infarction and stroke in patients with acute coronary 
syndromes (ACS). Yet, ticagrelor was found superior over clopidogrel in decreasing mortality 
in these patients and the underlying mechanisms are not entirely understood. Arterial 
thrombosis is the crucial step in ACS and the endothelium plays a pivotal role in mediating 
thrombus formation. However, possible off-target effects of P2Y12 antagonists on the 
endothelium and its key procoagulant factors such as tissue factor (TF), have not yet been 
investigated. Frequently, patients with ACS have comorbidities such as atrial fibrillation (AF) 
requiring anticoagulant therapy to prevent embolism of thrombi originating from left atrial 
appendages (LAA). Similar to endothelial cells, activation of LAA endocardial cells induces 
procoagulant TF and plasminogen activator inhibitor-1 (PAI-1) expression favouring 
thrombus formation in patients with AF. Whether certain P2Y12 antagonists possess 
antithrombotic properties on endocardial cells and may reduce thrombogenicity in AF 
patients has not yet been investigated. 
 
2.2 Material and methods  
Human aortic endothelial cells (HAECs) were incubated with ticagrelor or clopidogrel active 
metabolite (CAM) before stimulation with tumor necrosis factor-alpha (TNF-α); next, TF 
protein expression and enzyme activity as well as the underlying molecular mechanisms 
were investigated. Additionally, C57BL/6 mice were treated with ticagrelor or clopidogrel 
before endothelial TF expression was determined in common carotid arteries and 
photochemical-induced arterial thrombosis was compared between the groups. Finally, 
endocardial cells were isolated from LAA of 14 patients with AF undergoing elective cardiac 
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surgery. Endocardial cells were treated with ticagrelor or CAM and stimulated with TNF-α 
and TF as well as PAI-1 expressions and enzyme activities were analysed. 
 
2.3 Results 
Ticagrelor, unlike CAM, decreased TNF-α-induced TF activity and expression via 
proteasomal degradation in HAECs. These effects were mediated via the signalling 
molecules phosphoinositide 3-kinase and p70s6 kinase and independently of the P2Y12 
receptor and the equilibrative nucleoside transporter 1 (ENT1). Likewise, ticagrelor, but not 
clopidogrel, reduced endothelial TF expression in common carotid arteries of C57BL/6 mice 
and prolonged time to arterial thrombosis; meanwhile, platelet inhibition, plasma TF activity 
and systemic coagulation were comparable between the two groups. In LAA endocardial 
cells from AF patients, ticagrelor, unlike CAM, decreased TNF-α-induced TF and PAI-1 
protein expressions and enzyme activities. 
 
2.4 Conclusions 
Ticagrelor, but not clopidogrel, displays local antithrombotic properties on the endothelium 
and, compared with clopigorgel, reduces arterial thrombosis. Likewise, ticagrelor, but not 
CAM, exhibits local antithrombotic properties in AF patients by reducing expressions and 
activities of TF and PAI-1 in LAA endocardial cells. The specific antithrombotic properties of 
ticagrelor may contribute to the reduced mortality in ACS patients observed in clinical trials 
and may prevent systemic thromboembolism in patients with AF.  
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3 Introduction 
3.1 Epidemiology of cardiovascular disease 
Cardiovascular (CV) disease (CVD), including coronary heart disease and stroke, is the 
leading cause of death in Europe (Fig. 1)1, the United States of America2 and worldwide.3 In 
Europe, 4 million deaths per year are attributed to CVD, thereby representing 45 % of all 
deaths1. Interestingly, absolute and relative numbers of CV mortality are greater in women 
than in men, which is due to a higher number of cerebrovascular and “other CVD”, whereas 
coronary heart disease is comparable among both sexes (Fig. 1).1 
 
 
 
 
 
 
Figure 1. Deaths due to major causes in (A) men and (B) women in Europe. Source:1  
 
From 1990 to 2013, CV mortality increased from 12.3 to 17.3 million deaths worldwide, 
representing 25.9 % and 31.5 % of all non-communicable diseases, respectively.1 One 
explanation for this observation represents the ageing population4 since age is a major risk 
factor for the development of CVD.5 Ageing results from improved healthcare6 and better 
lifestyle conditions7 and is expected to continue in the near future causing substantial 
increase of disease burden and healthcare costs.4 Besides coronary heart disease and 
stroke, atrial fibrillation represents the most common cardiac arrhythmia with a prevalence of 
1.5 – 2 % in the general population and occurs at an average age of 75 – 85 years.8 In 
addition to the increased risk for mortality, thromboembolic complication, such as stroke, 
cause a significant disease burden and healthcare costs, which are estimated to further 
increase in the next decades.8  
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3.2 Endothelial function and dysfunction 
Vessel wall 
The vascular wall consists of an inner layer of endothelial cells, followed by vascular smooth 
muscle cells (VSMC) and adventitial cells9 (Fig. 2). The endothelial layer represents a roughly 
0.2 µm thick monolayer covering the whole vasculature and thereby an area of approximately 
3000 – 6000 m2, whereas the majority of cells are considered microvascular endothelial cells 
covering particularly capillaries.10 The volume of the entire endothelium is comparable to the 
volume of the liver.11 The endothelium preserves blood fluidity by preventing thrombus 
formation, adjusts tissue perfusion by regulating vascular tone, regulates vascular 
permeability and inflammatory responses, and plays a pivotal role during angiogenesis.11 
 
 
Figure 2. Arterial wall structure. The arterial wall is divided into the tunica intima containing ECs, the tunica 
media containing VSMCs and the tunica adventitia containing adventitial cells. EC = endothelial cell, VSMC = 
vascular smooth muscle cell. Source:9  
 
Endothelial function 
In healthy conditions, the endothelium prevents thrombus formation by physically separating 
platelets and coagulation factors from subendothelial prothrombotic mediators, such as 
collagen and tissue factor (TF)12, and by expressing anticoagulant mediators such as nitric 
oxide (NO)13,14, prostacyclin (PGI2)15, ectonucleotidase CD3916, tissue factor pathway inhibitor 
(TFPI)17 and antithrombin III18 among others. During resting state, endothelial cells do not 
interact with leukocytes since expression of adhesion molecules is down regulated and 
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chemokines are not secreted.19 Vascular tone is regulated via various vasoactive substances 
causing vasodilatation, such as NO, prostacyclin, adenosine and hydrogen peroxide (H2O2) 
or mediators causing vascular contraction, such as thromboxane A2, endothelin, angiotensin 
II, superoxide anion (O2-) but also hydrogen peroxide.11  
 
Endothelial dysfunction and reactive oxygen species 
Endothelial dysfunction is characterised by reduced vasodilatatory properties or a shift 
toward a proinflammatory or a prothrombotic state20; it is associated with aging, diabetes, 
hypertension and atherosclerosis11 and predicts CV outcome in patients with peripheral 
arterial disease21, atherosclerosis22, ACS23 and heart failure.24 
 
Despite the complexity of the pathogenic mechanisms leading to ED, oxidative stress is 
considered a central player in this respect.11 Relevant reactive oxygen species (ROS) for 
vascular pathology include NO, superoxide anion, hydrogen peroxide and peroxynitrite 
(ONOO-).25 NO is produced by endothelial NO synthase26 and by inducible NO synthase in 
endothelial cells, macrophages and VSMCs during inflammatory state.27 It causes 
endothelial-dependent vasodilatation13,14, inhibits platelet adhesion28 and aggregation29, and 
adhesion of leukocytes by inhibiting the expression of adhesion molecules.20 Superoxide 
anion is produced by various enzymes including NO synthase, nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase and xanthine oxidase30 and occurs in all cell types. 
In the presence of superoxide anion, NO reacts to ONOO-, which causes oxidation of 
proteins, deoxyribonucleic acids and lipids31 leading to the formation of oxidized low-density 
lipoprotein (LDL)25 among others. Alternatively, O2- is reduced to H2O2 by superoxide 
dismutase and finally dismutated to water and oxygen by catalase or glutathione 
peroxidase.11 In the presence of copper and ion or superoxide however, H2O2 forms highly 
reactive hydroxyl radicals (OH).11  
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ROS affect endothelium-derived vasorelaxation by uncoupling NO synthase thus reducing 
the bioavailability of NO and by inhibiting the downstream NO target guanylyl cyclase.11 Also, 
ROS cause vasoconstriction by multiple mechanisms including increased release of calcium 
from the sarcoplasmatic reticulum32 and activation of cyclooxygenase-1 and subsequent 
production of endothelium-derived contracting factors.33 Further, ROS induce the expression 
of endothelial adhesion molecules34 and monocyte chemoattractant protein-135 enhancing 
leukocyte-endothelium interaction and thereby modulating inflammatory responses.  
 
3.3 Atherosclerosis 
Atherosclerosis may be defined as a thickening and loss of elasticity of arterial walls due to 
atherosclerotic plaque formation36,37 typically affecting the subendothelial intima of large and 
medium-sized arteries.38 Atherosclerotic plaques consist of connective tissue, such as 
collagen and proteoglycans, cholesterol and phospholipids as well as cellular components 
including macrophages/foam cells, T-lymphocytes and VSMC36-38 (Fig. 3). 
 
ED, a shift of the endothelium towards a prothrombotic and proinflammatory state with a 
reduced vasodilatory capacity, is driven by classical CV risk factors such as dyslipidaemia, 
diabetes and hypertension11 and is considered a precursor of atherosclerosis.39 ED causes 
increased permeability and leukocytes adhesion to the endothelium40 (Fig 3 B). During the 
early phase of plaque formation, intimal thickening occurs due to accumulation of connective 
tissue, particularly proteoglycans, followed by lipid deposition41 (Fig. 3C). 
Lipoproteins containing apolipoprotein B, such as LDL and presumably lipoprotein(a), are of 
particular importance for plaque development. LDL accumulates in the subendothelial space 
through binding to extracellular connective tissue, i.e. proteoglycans.42 Interaction of LDL with 
proteoglycans depends on LDL size and density, whereas small and dense particles possess 
higher binding capacities.42 LDL retention increases susceptibility of multiple lipoprotein 
modifications such as self-aggregation, cleavage and oxidation, thereby transforming LDL 
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particles proatherogenic, finally, leading to the progression of atherosclerotic plaque 
formation.42 Indeed, oxidized LDL has been demonstrated in human atherosclerotic 
plaques.43 From a clinical perspective, plasma levels of LDL strongly correlate with the 
development of atherosclerosis.44 Consistently, reduction of LDL has been shown to reduce 
the risk for CV events45 strongly supporting a causal concept between LDL cholesterol and 
atherosclerosis development and progression. 
 
 
Figure 3. Atherosclerosis development. A) Healthy arterial wall. B) Initiation of atherosclerosis by 
transmigration of leukocytes and subsequent foam cell formation of monocytes through lipid uptake. C) 
Progression of atherosclerotic lesion through VSMC proliferation and migration, production of extracellular matrix 
connective tissue, apoptosis of macrophages and finally, accumulation of apoptotic bodies forming a necrotic 
core. D) Fibrous cap rupture and subsequent formation of an arterial thrombus through interaction of platelets and 
coagulation factors. Source: 36 
 
Endothelial transmigration of leukocytes including monocytes and T-lymphocytes (Fig. 3B) 
depends on the expression of endothelial adhesion molecules40 and is mediated by 
chemoattractants46,47, which can be stimulated by oxidized LDL.46 Furthermore, both LDL 
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aggregation48 and oxidation stimulate LDL uptake in macrophages49 through scavenger 
receptors50 finally leading to LDL degradation, intracellular lipid deposition and foam cell 
formation.51 Scavenging of oxidized LDL through macrophages may reduces detrimental 
effects on surrounding cells, such as endothelial cells or VSMC; nevertheless, progressive 
lipid deposition magnifies inflammatory responses and overcomes such compensatory 
mechanisms of macrophages.40 After adherence and migration, T-lymphocytes are in turn 
activated by macrophages through presentation of oxidized LDL52 and secretion of cytokines 
including interferon-y and tumor necrosis factor-alpha (TNF-α).53 Likewise, monocytes that 
transform to proinflammatory M2 macrophages secrete proinflammatory cytokines54 thereby 
further enhancing the inflammatory response. Some foam cells undergo apoptosis followed 
by necrosis and release lipids, which together with necrotic cell components form the necrotic 
core in atherosclerotic plaques.55 
 
In addition to monocytes and leukocytes, VSMC contribute to atherosclerotic plaque 
formation either by proliferation of VSMC in the intima, present in human arteries56, or 
migration from the VSMC layer of the vessel37 (Fig. 3C). Recently it has been proposed that 
in addition to local VSMC, bone marrow-derived stem cells contribute to atherosclerotic 
vascular pathology by homing, differentiation and migration.57 VSMC secrete connective 
tissue like collagen and elastin, which together build the fibrous cap covering the 
atherosclerotic plaques and preventing plaque rupture36 (Fig. 3D).  
 
3.4 Tissue factor and initiation of the coagulation cascade 
Tissue factor 
TF is a transmembrane glycoprotein, which initiates the extrinsic coagulation cascade by 
binding coagulation factor VII58, thereby activating factor IX and X59 finally resulting in 
thrombin and subsequent fibrin formation.60 Full length TF is a 47-kDa protein encoded by 6 
exons located at chromosome 1 and comprises 263 amino acids, whereas the extracellular 
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domain consists of residues 1 – 219, the transmembrane domain of residues 220 – 242 and 
the cytoplasmic domain of residues 243 – 263.58 The factor VII binding side is located at the 
extracellular domain.61 In addition to full length TF, alternatively spliced TF has been 
described, which lacks exon 5.62 Therefore, alternatively spliced tissue factor contains only 
206 amino acids, whereas residues 1 – 166 are identical to full length TF62 representing its 
extracellular domain and contain the factor VII binding side;61 thus alternatively spliced TF is 
considered to be able to initiate coagulation.62 The remaining residues 167 – 206 differ from 
full length TF due to a frameshift mutation and represent a unique C-terminus.62 Since the 
transmembrane domain is not expressed, alternatively spliced TF is soluble and circulates in 
blood.62 Possible sources of alternatively spliced TF include monocytes62 and endothelial 
cells.63 Alternatively spliced TF has been detected in human thrombi and is believed to 
contribute to thrombogenicity;62 however, its procoagulant activity was not proven by 
others64,65 and therefore its role in thrombosis is unclear. In addition to active cell surface TF, 
inactive and so called “encrypted” TF has been described.66 Like active TF, it binds factor VII, 
however, does not activate factor X sufficiently to prompt procoagulant activity.66 
Transformation to the active form is mediated by protein-disulfide isomerase67 and has been 
shown to be crucial for fibrin generation and thrombus formation in mice.68 
 
TF is expressed in endothelial cells69, VSMCs, the adventitia70, monocytes71, platelets and on 
circulating TF-containing microparticles released from platelets72,73, endothelial cells and 
monocytes.74 Furthermore it is expressed not only in the necrotic core of atherosclerotic 
plaques, but also in macrophages and the endothelium covering human atherosclerotic 
plaques.70,75,76 In physiological conditions only spare amount of TF are found in endothelial 
cells; however, during pathological conditions, such as high shear flow as occurring in a 
stenosed vessel77 and in the presence of various inflammatory cytokines such TNF-α and 
interleukin 178 as well as thrombin79, CD40 ligand80 and oxidized LDL81, TF expression is 
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increased in endothelial cells. Likewise, interleukin 1 induces tissue factor expression in 
monocytes82 and CD40 ligand in monocytes83 and VSMCs.84  
 
Initiation of the coagulation cascade 
Tissue factor represents a cellular receptor for the plasma serine protease factor VII or the 
activated form, factor VIIa85 (Fig. 4). Binding of TF enhances factor VII activation to VIIa86 and 
binding of TF is essential to increases factor VIIa enzyme activity in order to activate factor IX 
and factor X to factor IXa and Xa, respectively.85 Activation of factor VII to factor VIIa is further 
mediated by factor IXa and Xa87 as well as factor VIIa itself.88 Next, factor Xa forms the 
prothrombinase complex with factor Va on TF-containing cells,89 thereby transforming small 
amounts of prothrombin to thrombin, which subsequently amplifies the coagulation signal by 
activating factor V, VIII and XI on platelet surfaces90 (Fig. 4). Finally, thrombin transforms 
fibrinogen to fibrin91 and activates platelets by cleavage of protease-activated receptors.92 
 
 
Figure 4. Coagulation system. TF binds activated factor VII (VIIa) and activates factor X and factor IX. Factor Xa 
leads to the production of small amounts of thrombin, which in turn activates factor V (cofactor of factor X), factor 
VIII (cofactor of factor IX) and factor XI. Factor XIa further enhances factor IX activation. Factor IXa together with 
cofactor VIIIa (tenase complex) increase factor X activation. Finally, factor Xa binds factor Va (prothrombinase 
complex) and increases thrombin production substantially. TF = tissue factor. Source:86 
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In order to preserve an antithrombotic endothelial cell surface in physiologic condition, TFPI 
counteracts TF-mediated activation of coagulation and subsequent thrombus formation93. 
TFPI is expressed in endothelial cells under quiescent conditions and, like TF, can be 
upregulated upon activation by inflammatory cytokines.94 TFPI directly inhibits factor Xa,93 
most efficiently if factor Xa is integrated in the prothrombinase complex with factor Va, calcium 
ions and phospholipids.95 In addition, TFPI inhibits the TF/factor VII(a) through complexing 
with TF/factor VII(a) and Xa.93 
 
Experimental and clinical studies 
Experimental data revealed reduced arterial thrombus formation in low-TF expressing mice 
thus suggesting a pivotal role of vascular TF in thrombus formation.96 Transgenic mice 
deficient in murine TF and expressing 1% of human tissue factor, revealed prolonged arterial 
occlusion times after photochemical injury of the carotid artery using bengal rose.96 Neither 
did transplantation of low-TF bone marrow to wild-type animals increase, nor did 
transplantation of wild-type bone marrow to low-TF animals decrease arterial occlusion times 
confirming the relevance of vascular- rather than blood cell-derived TF in arterial thrombus 
formation.96 In addition, anti-TF antibody treated rabbits displayed reduced arterial thrombus 
formation after injury and subsequent stenosis of the common carotid artery.97 In clinical 
studies, increased levels of TF have not only been associated with cardiovascular risk factors 
including smoking98, hypertension99, diabetes100 and dyslipidaemia101 but also with acute 
coronary syndrome (ACS)102 emphasizing the clinical relevance of TF.  
 
3.5 Platelets and the P2Y12 receptor 
Platelets 
Human platelets are anucleated blood cells derived from bone marrow magakaryocytes with 
an average life span of 9 to 10 days.103 Despite the lack of DNA, platelets contain 
  18 
megakaryocyte-derived messenger RNA104 and are capable of protein synthesis.105 One-
hundred-fifty x 109 to 400 x 109 human platelets per litre of blood103 are present in the 
circulation, which are in turn surrounded by 3000 – 6000 m2 of endothelial surface.10 In 
physiological conditions, the endothelium prevents platelet adhesion and aggregation by 
separating platelets from the subendothelial matrix, by inhibiting platelets through NO13,14 and 
PGI215 and by inhibiting platelet agonists through antithrombin III18 and adenosine 
diphosphate (ADP) metabolism, among others.106 During resting state platelets appear 
round/oval whereas upon endothelial damage, platelets adhere to the side of injury, become 
activated and aggregate, which results in profound shape changes such as cellular 
spreading.12 Platelet are crucial to sustain haemostasis in case of injury; however, they may 
cause thrombus formation, subsequent vascular occlusion and tissue ischemia in 
pathological conditions.12  
 
In case of vascular injury or endothelial disruption, subendothelial extracellular matrix 
containing different types of collagens, von Willebrand factor (vWF), fibronectin and laminin is 
exposed to the blood stream107 (Fig. 5A). In high shear conditions as observed in the arterial 
circulation or in stenosed vessels, binding of the platelet receptor glycoprotein (GP) Ibα, part 
of the GPIb-V-IX complex, to extracellular vWF or plasma-derived vWF bound to 
subendothelial collagen, is crucial for platelet tethering.108 Yet, additional interactions of 
platelet GPVI and/or integrin α2ß1 with collagen, platelet integrin α5ß1 with fibronectin or 
platelet integrin α6ß1 with laminin is required for platelet adhesion.109 Adhesion of platelets to 
extracellular matrix proteins, particularly collagen and vWF, activates the platelet integrin 
αIIbß3 receptor allowing binding of several ligands such as soluble vWF, fibrinogen and fibrin 
and by that cross-linkage of platelets, a key step in firm adhesion and platelet 
aggregation12,107 (Fig. 5B). In parallel platelets produce thromboxane A2 and release dense 
granules containing ADP and α granules containing vWF, fibrinogen, fibronectin, p-selectin 
and interleukin 1 beta (Fig. 5A), which amplify platelet activation (ADP, thromboxane), 
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facilitate platelet-endothelium interaction (vWF, fibronectin), platelet-leukocyte interaction 
(fibronectin, fibrinogen p-selectin), leukocyte-endothelium interaction (p-selectin, interleukin 1 
beta), platelet aggregation (vWF, fibrinogen) and finally, fibrin clot formation (fibrinogen, 
factor V).12,109  
 
 
Figure 5. Platelet activation and aggregation. A) Platelet tethering to the vessel wall is mediated via GPIb-V-IX 
binding to subendothelial vWF. In addition, platelet GPVI and/or integrin α2ß1 binding to collagen is required for 
platelet adhesion and leads to activation of the αIIbß3 receptor, thromboxane A2 production and release of dense 
and α granules containing ADP, vWF, fibrinogen, fibronectin, p-selectin and interleukin 1 beta further enhancing 
platelet activation and aggregation. In addition, platelets are activated by other agonists such as thrombin. B) 
Finally, activated αIIbß3 receptor binds soluble vWF, fibrinogen and fibrin and mediates cross-linkage and thus, 
platelet aggregation. ADP = adenosine diphosphate, GP = glycoprotein, vWF = von Willebrand factor. Source:12  
 
Adenosine diphosphate and the P2Y receptors 
The released of ADP from dense granules, stimulated by collagen and thrombin,110 causes 
significant amplification of platelet activation by auto- or paracrine binding to platelet purine 
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receptors P2Y1111 and P2Y12.112 Purine and pyrimidine receptors are divided in P1 receptors 
selective for adenosine and P2 receptors, which are further divided in the ligand-gated ion 
channels P2X receptors and the G protein-coupled P2Y receptors.113 Binding of ADP to the 
metabotropic Gq-coupled P2Y1 receptor results in phospholipase C activation, subsequent 
increase of inositol triphosphate and rise of cytosolic calcium from intracellular stores.113 
Instead, activation of the metabotropic Gi-coupled P2Y12 receptor leads to an inhibition of the 
adenylyl cyclase and subsequent decrease of cyclic adenosine monophosphate.113 In 
addition, the P2Y12 receptor activates phosphoinositide 3-kinase (PI3K) and thereby the αIIbß3 
receptor.114 Activation of the P2Y1 leads to platelet shape change and transient aggregation, 
whereas activation of the P2Y12 receptor results in dense granule secretion and sustained 
platelet aggregation.110 In summary, activation of both receptors is necessary to grant full 
platelet aggregation since blockade of each receptor individually reduces platelet 
aggregation.115 Interestingly, inhibition of both receptors in parallel shows synergistic 
effects.116 
 
3.6 P2Y12 receptor antagonists 
Due to the crucial role of platelets in arterial thrombus formation, platelet antagonists are 
routinely used in the clinic to reduce thrombogenesis and prevent cardiovascular 
complications such as myocardial infarction (MI) and stroke.6 Beside from established 
platelet antagonists including the cyclooxygenase-1 antagonist aspirin6, integrin αIIbß3 
antagonists117 and emerging inhibitors of GPIV118, GPIb119 and thromboxane A2 receptors120, 
platelet ADP receptor P2Y12 antagonists have been shown to reduce major adverse cardiac 
events in large clinical trials.121-124 Currently four P2Y12 receptor antagonists are approved for 
clinical use including clopidogrel, prasugrel, ticagrelor and cangrelor, whereas the first 
approved P2Y12 receptor antagonist ticlopidine has been replaced due to adverse 
haematological side effects125 and development of elinogrel was discontinued recently.126 
P2Y12 receptor antagonists can be divided into thienopyridines including ticlopidine, 
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clopidogrel and prasugrel, in cyclopentyl-triazolo-pyrimidines including ticagrelor and in the 
adenosine triphosphate analogue cangrelor.127  
 
The thienopyridines clopidogrel and prasugrel 
Thienopyridines are indirect pro-drugs requiring conversion to the active metabolite by 
hepatic cytochrome P450 enzymes before irreversibly binding the P2Y12 receptor.127 
Pharmacokinetic and pharmacodynamic properties differ significantly among P2Y12 receptor 
antagonist. Clopidogrel not only exhibits weak inhibition of ADP-induced platelet aggregation 
with great inter-individual variability128 but also 15 to 30 % of patients respond only marginally 
to clopidogrel treatment.129 Importantly, higher platelet reactivity to ADP despite clopidogrel-
treatment is associated with an increased risk of major adverse cardiac events.129 Such non-
responsiveness might be due to incompliance, differences in intestinal absorption and P2Y12 
receptor polymorphisms;129 however, it has been proposed that variations in the cytochrome 
P450 3A4 considerably influences hepatic activation of clopidogrel.130 Surprisingly, treatment 
adjustment in non-responders to clopidogrel did not improve cardiovascular outcome.131 
Compared to clopidogrel, prasugrel shows a faster onset and higher level of platelet inhibition 
as well as a reduced inter-individual variability and lower non-responsiveness132,133 due to a 
more efficient conversion of prasugrel to its active metabolite.134 Consequently, prasugrel, 
compared with clopidogrel, reduced the primary composite endpoint, the rate of death from 
cardiovascular causes, non-fatal MI, or non-fatal stroke in ACS patients.122 On the other 
hand, prasugrel increased major bleeding events and therefore, did not reduce overall 
mortality in these patients.122 
 
The cyclopentyl-triazolo-pyrimidine ticagrelor 
Ticagrelor and cangrelor are direct acting drugs, do not need hepatic transformation and bind 
to the P2Y12 receptor reversibly.127 Ticagrelor, similarly to prasugrel, exhibits a faster onset, a 
greater level of and a more rapid offset of inhibition of ADP-induced platelet aggregation.135 
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Due to reversible binding, ticagrelor may be more protective from platelet aggregation in 
patients with high platelet turnover due to a more sustained platelet inhibition of newly formed 
(reticulated) platelets.136 Patients with higher number of reticulated platelets are at higher risk 
for cardiovascular events.137 Correspondingly, aggregation of immature platelets correlated 
with prasugrel, but not ticagrelor-treated patients with ACS.138 In large randomized clinical 
trials, ticagrelor proved higher efficacy, compared with clopidogrel in ACS patients; ticagrelor 
reduced the primary composite endpoint, death from vascular causes, MI and stroke without 
increasing the primary safety endpoint, major bleedings although fatal intracranial and non-
intracranial bleeds were higher in ticagrelor-treated patients121. Importantly, ticagrelor, 
compared with clopidogrel, also reduced overall mortality.121 Furthermore, in patients with 
prior MI, ticagrelor, compared with clopidogrel, reduced cardiovascular death, MI and stroke, 
but also increased major bleedings.139 
 
Pleiotropic effects of P2Y12 receptor antagonists 
Thienopyridines were shown to have multiple pleiotropic effects.140 In apolipoprotein E-
deficient mice prone to atherosclerosis, clopidogrel treatment reduced atherosclerotic lesion 
size by roughly one third, compared to control animals.141 Anti-inflammatory properties have 
been described for prasugrel; in a mouse model for endotoxic shock syndrome, prasugrel 
reduced platelet p-selectin expression and platelet-leukocyte interaction as well thromboxane 
2 and TNF-α production.142 Both, ticlopidine and clopidogrel were found to mediate 
endothelial-dependent vasodilatation in pre-contracted arteries of rats.143 In patients with 
coronary artery disease and peripheral endothelial dysfunction, single dosages of clopidogrel 
dose-dependently reduced endothelial dysfunction as assessed by flow-mediated dilatation 
of the brachial artery.144  
Like for thienopyridines, pleiotropic effects have been described also for ticagrelor.140,145 In 
addition to the P2Y12 receptor, ticagrelor, but not thienopyridines or cangrelor, binds to the 
equilibrative nucleoside transporter 1 (ENT1),146 which is expressed in red blood cells among 
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many others,147 and reduces adenosine uptake.146 Consequently, ticagrelor decreased 
adenosine uptake in human red blood cells148 and increased plasma levels of adenosine in 
ACS patients treated with ticagrelor.149 Adenosine inhibits platelet activation150 and was found 
to contribute to platelet inhibition in human whole blood treated with ticagrelor.151 
Furthermore, ticagrelor, but not prasugrel or clopidogrel, reduced VSMC contraction in rats;152 
Treatment with ticagrelor revealed anti-inflammatory properties by reducing pulmonary 
oedema, neutrophil recruitment and lung damage in mice exposed to experimental 
abdominal sepsis.153 In addition, ticagrelor, unlike clopidogrel, reduced MI in rats154 and in 
pigs in an adenosine-dependant manner.155 In patients with prior ACS, ticagrelor, compared 
with clopidogrel and prasugrel, improved peripheral arterial function after forearm 
ischemia.156 Such additional pleiotropic effects may in part contribute to the differences in 
outcomes observed in randomized controlled trials comparing P2Y12 inhibitors. 121,139 
 
3.7 Atherothrombosis 
Arterial thrombosis on top of an atherosclerotic lesion is the key event in ACS and results 
from interactions between the vessel wall, blood cells including platelets, red blood cells and 
leukocytes and the coagulation system.86,157-160  
 
Atherosclerotic plaques 
Complex atherosclerotic lesions prone to rupture and to cause arterial thrombosis usually 
present a thin fibrous caps, are large in size and cause a small luminal area;161 they typically 
cause expansive vascular remodelling and exhibit low calcification.162 Furthermore, they 
contain a large lipid core, numerous leukocytes and fewer VSMC.163 
During the early stage of plaque development, atherosclerosis causes vascular enlargement 
by expansive growth, which compensates vascular stenosis through the newly formed 
plaque; therefore, stenosis occurs late during plaque development.164 Plaque rupture rather 
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than superficial erosions of the fibrous caps overlying the lipid or so-called necrotic core, 
causes the majority of fatal coronary thrombosis.165 
Plaque rupture is associated with thin fibrous caps166 and its stability is believed to be 
mediated primarily through collagen, which is synthetized by VSMCs and degraded by some 
matrix-metalloproteinases.159 Accumulation of T-lymphocytes and macrophages, however, 
reduces collagen synthesis by inhibiting VSMCs and increase collagen breakdown by 
producing matrix-metalloproteinases, respectively.159 In contrast to plaque rupture, plaque 
erosion is believed to be triggered primarily by endothelial apoptosis due to increased 
oxidative stress from activated leukocytes, which also increases up-regulation of pro-
coagulant TF.159 Interestingly, statin therapy not only reduces plasma low-density lipoprotein 
and lipid content of atherosclerotic plaques but also decreases atherosclerotic plaque 
macrophage activity, which may contribute to its well-defined cardiovascular protective 
effects.167 Also, anti-inflammatory therapy with low-dose colchicine reduced cardiovascular 
events in patients with stable coronary artery disease168 highlighting the importance of 
inflammation in atherosclerosis and subsequent arterial thrombosis. 
 
Platelet adhesion, activation and recruitment 
Upon plaque erosion or rupture due to underlying inflammatory mechanisms159, 
subendothelial extracellular matrix is exposed. In high shear conditions, as occurring in the 
arterial vasculature, vWF is essential for platelet tethering108 and subsequent binding of 
various platelet receptors to subendothelial collagen, fibrinogen and laminin enables platelet 
adhesion109. Platelet adhesion triggers release of platelet granules containing ADP and 
thromboxane, which enhances platelet activation.12,109 Next, integrin αIIbß3 receptors become 
activated and, together with platelet GPIb, binds vWF and other soluble molecules, whereby 
additional platelets are recruited and aggregate at the side of plaque erosion or rupture.12,107  
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Initiation, amplification and propagation of the coagulation cascade 
In parallel to platelet recruitment, the coagulation cascade is initiated by TF.157 Exposure of 
TF and subsequent binding of factor VII/factor VIIa85 activates factor IX and factor X.85 Next, 
factor Xa forms the prothrombinase complex with factor Va on TF-containing containing 
cells89, which leads to the formation of small amounts of thrombin.91  
 
Following initiation of the coagulation cascade, thrombin not only leads to platelet activation 
via cleavage of protease-activated receptors 1 and 492 but also activates co-factor V, co-
factor VIII and factor XI on platelet surfaces thereby amplifying the procoagulant signal.90 
During the propagation phase, large amounts of thrombin are produced.90 After thrombin-
mediated activation of factor XI to XIa, factor XIa activates factor IX to IXa, which binds factor 
VIIIa and thus forms the tenase complex activating factor X to Xa; factor Xa complexes with Va 
and increases thrombin.86 Finally, thrombin transforms fibrinogen to fibrin, which 
subsequently polymerizes to fibrin strands.91 Lastly, after activation by thrombin among 
others, factor XIIIa stabilizes polymerized fibrin strands to form a stable platelet clot.169 
 
3.8 State of research in the field  
In addition to aspirin, P2Y12 receptor antagonists including clopidogrel, prasugrel and 
ticagrelor are crucial to reduce MI, stroke and CV death in patients suffering an ACS as 
shown in large randomized controlled trials.121-123 Both prasugrel and ticagrelor exhibit 
greater inhibition of ADP-induced platelet aggregation, as compared with clopidogrel.132,135 
Yet, despite comparable efficacy in platelet inhibition170 only ticagrelor, but not prasugrel, 
reduced overall mortality in ACS patients, as compared with clopidogrel.121,122 Recently 
described pleiotropic anti-inflammatory153 and vasodilative effects152 of ticagrelor as well as 
the ability to inhibit the adenosine transporter ENT1, may in part explain this observation. 
Nevertheless, P2Y12 receptors are not only expressed in platelets but also in the vessel 
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wall171 and platelet-independent vascular effects of P2Y12 antagonists on arterial 
thrombogenesis remain unknown.  
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Abstract 
Aims 
The P2Y12 antagonist ticagrelor reduces mortality in patients with acute coronary syndrome 
(ACS), compared with clopidogrel, and the mechanisms underlying this effect are not clearly 
understood. Arterial thrombosis is the key event in ACS; however, direct vascular effects of 
either ticagrelor or clopidogrel with focus on arterial thrombosis and its key trigger tissue 
factor have not been previously investigated. 
Methods and Results 
Human aortic endothelial cells were treated with ticagrelor or clopidogrel active metabolite 
(CAM) and stimulated with tumor necrosis factor-alpha (TNF-α); effects on procoagulant 
tissue factor (TF) expression and activity, its counter-player TF pathway inhibitor (TFPI) and 
the underlying mechanisms were determined. Further, arterial thrombosis by photochemical 
injury of the common carotid artery, and TF expression in the murine endothelium were 
examined in C57BL/6 mice treated with ticagrelor or clopidogrel. Ticagrelor, but not CAM, 
reduced TNF-α-induced TF expression via proteasomal degradation and TF activity, 
independently of the P2Y12 receptor and the equilibrative nucleoside transporter 1 (ENT1), an 
additional target of ticagrelor. In C57BL/6 mice, ticagrelor prolonged time to arterial occlusion, 
compared with clopidogrel, despite comparable antiplatelet effects. In line with our in vitro 
results, ticagrelor, but not clopidogrel, reduced TF expression in the endothelium of murine 
arteries. 
Conclusion 
Ticagrelor, unlike clopidogrel, exhibits endothelial-specific antithrombotic properties and 
blunts arterial thrombus formation. The additional antithrombotic properties displayed by 
ticagrelor may explain its greater efficacy in reducing thrombotic events in clinical trials. 
These findings may provide the basis for new indications for ticagrelor. 
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Introduction 
 
Cardiovascular disease is the leading cause of death worldwide1. Platelets play a crucial role 
in arterial thrombus formation, the key event in cardiovascular complications, such as 
myocardial infarction and stroke. Consequently, platelet antagonists targeting the adenosine 
diphosphate (ADP) receptor P2Y12 (i.e. clopidogrel, prasugrel, or ticagrelor) in combination 
with acetylsalicylic acid is the treatment of choice for patients suffering from acute coronary 
syndrome (ACS) and for secondary prevention after stent implantation or coronary artery 
bypass grafting2. In clinical trials ticagrelor and prasugrel proved to be superior over 
clopidogrel3,4; in particular, ticagrelor reduced the composite end point mortality due to 
vascular causes, myocardial infarction or stroke in addition to overall mortality in patients with 
ACS, compared with clopidogrel3. The cyclopentyl-triazolo-pyrimidine ticagrelor displays a 
different pharmacokinetic and pharmacodynamic profile, compared with the thienopyridines 
clopidogrel and prasugrel. Specifically, ticagrelor is direct acting and reversibly binding the 
P2Y12 receptor, whereas the thienopyridines are pro-drugs requiring hepatic metabolism to 
generate an irreversibly binding active metabolite. Higher levels of platelet inhibition 
complemented by an additional mechanism of action, the inhibition of cellular adenosine 
uptake via the equilibrative nucleoside transporter 1 (ENT1)5-8 leading to increased 
adenosine plasma levels9, may in part account for the superior effects of ticagrelor. 
A growing body of evidence suggests off-target effects of P2Y12 antagonists; however, effects 
of ticagrelor and clopidogrel on the endothelium, their underlying molecular mechanisms and 
potential effects on arterial thrombosis remain elusive. 
Tissue factor (TF) is the key trigger of the extrinsic coagulation cascade10 and plays a major 
role in the development of arterial thrombotic complications such as myocardial infarction and 
stroke11. Correspondingly, anti-TF antibody treatment blocks arterial thrombus formation12. 
Increased levels of TF have been observed in patients with classical cardiovascular risk 
factors, such as hypertension13, diabetes14 and dyslipidaemia15, as well as in ACS16. TF is 
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expressed in various cell types including endothelial cells and different cytokines such as 
tumor necrosis factor-alpha (TNF-α) are known to induce TF expression and activity17. 
Correspondingly, elevated levels of TNF-α have also been reported in patients with ACS18 
and atrial fibrillation19 and are further associated with cardiovascular disease progression and 
severity20. 
In the present study, we investigate pleiotropic effects of ticagrelor and clopidogrel on TNF-α-
stimulated primary human aortic endothelial cells (HAECs), assess the underlying 
mechanisms and their potential relevance in a mouse model of photochemical injury-induced 
arterial thrombosis. 
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Methods 
 
Drugs 
Clopidogrel active metabolite (CAM) and ticagrelor were provided by Sanofi-Aventis, 
Germany and AstraZeneca, Mölndal, Sweden, respectively. Clopidogrel was purchased from 
Santa Cruz Biotechnology. 
 
Animals and treatment 
Twelve-week-old bodyweight-matched male C57BL/6 mice were treated with clopidogrel (48 
mg/kg/day or 32 mg/kg/day) or ticagrelor (120 mg/kg/day or 80 mg/kg/day) given in the chow 
(clopidogrel, 0.06% w/w or 0.04 w/w; ticagrelor, 0.15% w/w or 0.1% w/w), for 2 weeks to 
evaluate dosages that provide full and comparable platelet inhibition in mice. Dosages of 
clopidogrel and ticagrelor differed 2.5 fold corresponding to dosages used in humans2 and 
dosages known to provide comparable platelet inhibitory effects in rodents21. Experimental 
procedures involving mice were reviewed and approved by the institutional animal care 
committee (licence number TVA 165/2013; Kommission für Tierversuche des Kantons 
Zürich, Zurich, Switzerland). 
 
Plasma concentrations of ticagrelor 
In addition to pharmcodynamic evaluation of P2Y12 receptor antagonist treatment, ticagrelor 
plasma concentrations were determined by protein precipitation and liquid chromatography 
mass spectrometry as described previously22. 
 
Whole blood aggregometry 
Sodium-citrate (3.8%) anticoagulated blood was collected by cardiac puncture using a 24-
gauge needle after euthanasia of mice by isoflurane. Finally, whole blood (diluted 1 to 3 in 
0.9% saline) aggregometry was performed in response to ADP (10 µM; 384, chrono-log), 
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thrombin (1 U/mL; T7009, Sigma Aldrich) and collagen (10μg/mL; Kollagenreagens Horm, 
Takeda) by impedance aggregometer (Chrono-Log). 
 
Arterial thrombosis 
After 2 weeks of treatment with ticagrelor, clopidogrel or control chow, C57BL6 mice were 
exposed to photochemical injury of the common carotid artery (CCA) as previously 
described23. Briefly, mice were anaesthetized using pentobarbital (87 mg/kg body weight); 
after midline neck incision, the right CCA was exposed under an operating microscope. To 
induce photochemical injury of the endothelium, bengal rose (50 mg/kg body weight) was 
injected into the tail vein and the CCA was exposed to a laser light beam (1.5 mW, 540nm, 
Mellesgriot Inc.) up to 120 minutes. Blood flow and heart rate were monitored (Doppler flow 
probe carotid artery Transonic Systems Inc., 0.5VB) until occlusion occurred or for a 
maximum of 120 minutes, in case arterial thrombosis was not detected. 
 
Plasma thrombin generation 
Plasma thrombin generation was assessed by calibrated automated thrombogram as 
previously described24. Sodium-citrate (3.8%) anticoagulated murine whole blood was drawn 
by cardiac puncture and centrifuged (4’000 g, 10 min, 4°C) to receive platelet-poor plasma, 
which was then mixed with either PPP-Reagent (Thrombinoscope BV) containing TF (f.c. 6 
pM) and phospholipids (f.c. 4.8 μM), or thrombin calibrator (Thrombinoscope BV). Next, 
fluorogenic thrombin substrate (Thrombinoscope BV), Fluo-Buffer (Hepes buffer, pH 7.35, 20 
mM Hepes, with BSA 60 mg/ml, Thrombinoscope BV) and CaCl2 (246 mM) were added. 
Thrombin generation was measured over time by Fluoroskan® Ascent reader (Thermo 
Labsystems) and thrombin generation curve was calculated by Thrombinoscope software 
(Thrombinoscope BV) to finally receive endogenous thrombin potential (ETP) (nmol thrombin 
x min).  
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Endothelial tissue factor expression 
CCAs of mice were embedded in Optimal Cutting Temperature medium, snap frozen and 
cryosectioned. Sections were incubated with the primary antibodies rat anti-murine CD31 
(BD 553370, 1:2500), used as an endothelial cell marker, and rabbit anti-TF (R808425, 1:200) 
for 45 min at room temperature. After washing, the secondary antibodies donkey anti-rat Cy3 
(Jackson 712-166-153, 1:250) and donkey anti-rabbit Alexa488 (Jackson 711-545-15, 1:250) 
were applied for 45 min at room temperature. DNA was counterstained using UltraCruz Hard-
set Mounting medium containing 4',6-diamidino-2-phenylindole (Santa Cruz, sc-359850). 
Images were acquired using a Zeiss Axiovert inverted widefield fluorescence microscope with 
Axiovision software. Composite images were generated using Photoshop (CC2015, Adobe) 
and endothelial TF mean fluorescent intensity was quantified and normalized to endothelial 
cell area. 
 
Isolation of human platelets 
Human platelets were used as positive control of P2Y12 receptor mRNA and protein 
expression. Venous blood was drawn from a healthy volunteer not receiving any medication 
for 10 days and collected in sodium-citrate (3.8%) tubes (Becton Dickinson). Blood was 
centrifuged twice at 100 g for 10 minutes at room temperature to obtain platelet-rich plasma, 
which was centrifuged at 400 g for 15 minutes at room temperature. Finally, the platelet pellet 
was washed with 1 mL phosphate-buffered saline and after a final centrifugation step (400 g, 
10 min, room temperature) exposed to either protein lysis buffer or TRIzol for Western blot or 
real-time polymerase chain reaction (RT-PCR), respectively. 
 
Cell culture experiments 
HAECs (Lonza) were used for experiments between passage 5 and 8, derived from 4 
individual batches. Endothelial cells were cultured in endothelial growth basal medium-2, 
supplemented with endothelial growth basal medium-2 bullet kit (Lonza) and 10% fetal 
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bovine serum. After 24 hours of growth, cells underwent starvation for 24 hours using 
endothelial basal medium (Lonza) supplied with 0.5% fetal bovine serum. Cells were treated 
with concentration ranges of ticagrelor (10-7, 10-6, 10-5 M)26 or CAM (1.5 x 10-8, 1.5 x 10-7, 1.5 
x 10-6 M), which are in line with plasma concentrations found in humans26, and stimulated 
with TNF-α (10 ng/mL) for various time points. Drugs were dissolved in dimethyl sulfoxide 
(f.c. 0.1%). Correspondingly, unstimulated cells and TNF-α-stimulated cells were treated with 
dimethyl sulfoxide (f.c. 0.1%) to exclude vehicle-dependent effects. 
 
Western blotting 
Protein expression was determined by Western blot analysis. Endothelial cells and human 
platelets were incubated with lysis buffer (NaCl 150 mM, EDTA 1 mM, NaF 1 mM,  DTT 1 mM, 
aprotinin 10 mg/mL, leupeptin 10 mg/mL, Na3VO4  0.1 mM, PMSF 1 mM, and NP-40 0.5%); 
protein concentration was determined, according to the manufacturer’s recommendations 
(Bio-Rad); 20 – 30 µg of protein lysates were separated on an 8% or 10% sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis before being transferred   to a polyvinylidene 
fluoride membrane by semi-dry transfer. Membranes were cut, according to the size of 
proteins of interest and incubated with primary antibodies overnight at 4°C on a shaker. 
Secondary antibodies were applied for 1 hour at room temperature. Densitometric analyses 
were performed and protein expression was normalized to glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH). Antibodies against TF (ADG4507 and 4503; 1:2000) and tissue 
factor pathway inhibitor (TFPI) (ADG72; 1:8000) were purchased from American Diagnostica; 
anti-P2Y12 (ab86195; 1:2000) antibody from Abcam; anti-GAPDH antibody (MAB374; 
1:40000) from Merck Millipore. Secondary anti-mouse (1031-05) and anti-rabbit (4050-05) 
antibodies were obtained from SouthernBiotech; recombinant human TNF-α (210-TA) was 
purchased from R&D Systems; actinomycin D (A1410), MG132 (C2211), rapamycin (R0395), 
wortmannin (W1628), SB203580 (S8307), SP600125 (S5567), dipyridamole (D9766), 
adenosine receptor antagonist against A1 (8-cyclopentyl-1,3-dipropylxanthine), A2a (SCH 
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442416), A2b (MRS 1754) and A3 (VUF 5574) as well as adenosine (A4036) from Sigma 
Aldrich; cycloheximide (239765) from Merck Millipore; PD 98059 (9900) from Cell Signaling 
Technology. 
 
Real-time PCR 
Total RNA was extracted from HAECs or human platelets using TRI reagent (Sigma Aldrich), 
according to the manufacturer’s recommendations. Conversion of the total cellular RNA to 
cDNA was performed with Moloney murine leukemia virus reverse transcriptase and random 
hexamers (GE Healthcare) in a final volume of 35 μl, using 2 μg of total RNA, according to 
manufacturer’s recommendations. RT-PCR was performed in a QuantStudio 7 Flex RT-PCR 
cycler (Applied Biosystems), according to the manufacturer’s instructions. All RT-PCR 
experiments were performed using the SYBR Select Master Mix provided by Applied 
Biosystems (Life Technologies). Each reaction (20 μl) contained 2 μl cDNA, 400 fmol of each 
primer and 10 μl of Master Mix. The following primers were used: P2Y12 (1), P2Y12 (2), TF, 
human L28 and human β-actin (ACTB). The amplification program consisted of 1 cycle at 
95˚C for 10 min, followed by 40 cycles with a denaturing phase at 95˚C for 15 s, an 
annealing/elongation phase at 60˚C for 1 min. A melting curve analysis was performed after 
amplification to verify the accuracy of the amplicon. For verification of the correct 
amplification, PCR products were analyzed on an ethidium bromide stained 1.5% agarose 
gel. Cycle threshold (CT) values for each gene were obtained for each sample and 
differences in CT values between a test gene and endogenous controls (ΔCT) were calculated 
and used for statistical analyses. 
For quantitative RT-PCR the following primers were used; for human P2Y12: sense primer (1) 
5’-CTTTCTCATGTCCAGGGT-3’, antisense primer (1) 5’-GTTGCCAAACCTCTTTGT-3’; 
sense primer (2) 5’-TTTCTCATGTCCAGGGTC-3’, antisense primer (2) 5’-
CTGCAGAGTGGCATCTGG-3; for human TF: sense primer: 5’-
CCAAACCCGTCAATCAAGTC-3’, antisense primer: 5’-TGCCAAGTACGTCTGCTTCA-3’; for 
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human L28: sense primer: 5’-GCATCTGCAATGGATGGT-3’, antisense primer: 5’-
TGTTCTTGCGGATCATGTGT-3’; for ACTB: sense primer: 5’- GCACAGAGCCTCGCCTT -3’, 
antisense primer: 5’-GTTGTCGACGACGAGCG-3’.  All primers were ordered from 
Microsynth. 
 
Tissue factor activity assay 
TF activity was determined as previously described23 in cell lysates of HAECs and murine 
plasma by ELISA, according to the manufacturer’s recommendations (Sekisui Diagnostics, 
ACTICHROME® TF, 846). Endothelial cells were lysed (50 mmol/L Tris-HCl, 100 mmol/L 
NaCl, 0.1% Triton X-100, pH 7.4), diluted 1:15 in assay buffer, and mixed with human factor 
VIIa and X, which leads to conversion of factor X to Xa; factor Xa subsequently cleaves the 
chromogenic substrate SPECTROZYME® FXa. Finally, absorbance was measured at 405 
nm and after background subtraction, optical density was normalized to protein concentration 
as determined by Nanodrop 2000 Spectrophotometer (Thermo Scientific). Sodium-citrate 
(3.8%) anticoagulated plasma was mixed with factor VIIa and X and optical density of 
cleaved SPECTROZYME® FXa was determined at 490 nm and subtracted from absorbance 
at 405 nm. Finally, plasma TF (pM) was calculated, according to a standard curve. 
 
Tissue factor mRNA stability 
Stability of TF mRNA was investigated as previously described27. Endothelial cells were 
stimulated with TNF-α for 1 h to induce TF gene expression and transcription was 
subsequently terminated using actinomycin D (10 µg /mL). Next, cells were incubated with 
ticagrelor (10-5 M) for 1, 2, or 3 hours before cells were lysed with TRIzol. Messenger RNA 
was isolated and RT-PCR was performed. Values were plotted as percent of time 0 against 
time (min) and half-life was calculated by non-linear regression using Prism 6 (GraphPad 
software). 
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Statistical analysis 
Data are expressed as mean ± SEM. Statistical analysis was performed using one-way 
ANOVA with Tukey post hoc test or unpaired two-tailed Student’s t-test as appropriate. A 
probability value below or equal to 0.05 was considered as statistically significant and 
calculated by Prism 6 (GraphPad software). 
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 Results 
 
Ticagrelor, but not CAM, reduces TF expression and activity  
Ticagrelor concentration-dependently decreased TNF-α-induced TF expression in HAECs 
(Fig. 1A), whereas no effect was observed with increasing concentrations of CAM (Fig. 1B). 
In addition to protein expression, TF activity was reduced by ticagrelor, compared with 
vehicle-treated cells (Fig. 1C). On the other hand, protein levels of TFPI were not affected by 
ticagrelor or CAM (Supplementary Fig. 1). Preincubation with both the PI3 kinase inhibitor 
wortmannin and the mTOR inhibitor rapamycin partially reversed ticagrelor-mediated TF 
reduction (Fig. 1D and 1E), whereas co-incubation with both kinase inhibitors abolished the 
effect of ticagrelor (Fig. 1F). Preincubation using the MAP kinase inhibitors for JNK 
(SP600125, 10-6 M), ERK (PD98059, 10-7 M) or p38 (SB203580, 10-6 M) did not reverse 
ticagrelor-mediated reduction of TF expression (data not shown). 
 
Ticagrelor decreases endothelial TF by proteasomal degradation 
To investigate whether the reduction of TF protein expression was due to a decrease in TF 
gene expression, RT-PCR was performed. Contrary to protein expression, mRNA levels were 
increased by ticagrelor, compared with vehicle-treated cells (Fig. 2A), suggesting a 
compensatory mechanism for the decrease of tissue factor protein expression. Additionally, 
potential alterations of mRNA half-life were examined. To this end, actinomycin D was added 
to stop transcription 1 hour after TNF-α stimulation. Next, cells were incubated with ticagrelor 
or vehicle for an additional 1, 2, or 3 hours. No differences in mRNA levels between the 
groups were observed at any time point examined (Fig. 2B). To further evaluate the 
underlying mechanism on TF reduction, post-translational mechanisms were investigated, as 
previously described28. HAECs were stimulated with TNF-α for 3 hours, after which TF 
protein expression has been reported to reach a steady state28. Next, translation was 
arrested with cycloheximide and simultaneously, cells were incubated with ticagrelor or 
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vehicle for additional 2 hours. TF protein expression was not altered by cycloheximide, 
compared with TNF-α. However, ticagrelor significantly reduced TF protein expression, 
compared with vehicle-treated cells (Fig. 3A) suggesting that ticagrelor reduced TF protein 
stability. In line with this, the proteasome inhibitor MG-132 rescued the effect of ticagrelor on 
TF reduction (Fig. 3B) suggesting that ticagrelor reduces TF by proteasomal degradation. 
 
Effects of ticagrelor are mediated independently of P2Y12 or ENT1 
To investigate the presence of P2Y12 receptor in various endothelial cells, RT-PCR as well as 
Western blot experiments were performed using human platelets as positive control. 
Interestingly, P2Y12 mRNA was not detected in human endothelial cells of aortic, cerebral or 
cardiac origin by using two different pairs of primers for human P2Y12, whereas it was clearly 
found in human platelets (Fig. 4A). Next, expression of P2Y12 protein was investigated, which 
was detected in human platelets, but, excluding unspecific bands, could not be detected in 
any types of endothelial cells (Fig. 4B). The absence of P2Y12 mRNA and protein suggests 
that the observed effects of ticagrelor were mediated independently of the P2Y12 receptor. 
Next, we investigated whether the observed effects of ticagrelor were mediated by ENT1 
inhibition and subsequent increase of adenosine, as recently discussed8,21. Therefore, TNF-
α-stimulated cells were treated with increasing concentrations of adenosine to mimic the 
effects of ticagrelor. Indeed, we observed a concentration-dependent decrease of TF 
expression in HAECs (Fig. 5A). However, contrary to ticagrelor, adenosine decreased TF 
RNA expression suggesting a transcriptional regulation of TF (Fig. 5 B). Further, we did not 
observe similar effects using the ENT1 inhibitor dipyridamole (Fig. 5C). Correspondingly, 
preincubation of HAECs using adenosine receptor antagonists against A1 (8-cyclopentyl-1,3-
dipropylxanthine, 10-7 M), A2A (SCH 442416, 10-7 M), A2b (MRS 1754, 10-7 M) and A3 (VUF 
5574, 10-7 M)29,30 receptors individually (data not shown) or in combination did not reverse the 
effects of ticagrelor (Fig. 5D). 
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Ticagrelor decreases arterial thrombosis and endothelial TF expression in mice 
Whole blood aggregometry after 2 weeks of treatment with ticagrelor 0.15% and clopidogrel 
0.06% revealed equal and close to full (>97%) inhibition of ADP-induced platelet aggregation, 
as compared with animals treated with control chow (Fig. 6A); lower concentration, i.e. 
ticagrelor 0.1% and clopidogrel 0.04% provided subtotal platelet inhibitory effects (Fig. 6A). 
Treatment of rodents using ticagrelor 0.15% resulted in plasma concentration of 2.7 ± 0.7 uM 
(Fig. 6B). Also, platelet aggregation in response to thrombin (1U/mL) and collagen (10μg/mL) 
did not differ between ticagrelor- and clopidogrel-treated mice (data not shown). Mice treated 
with ticagrelor or clopidogrel showed prolonged arterial occlusion times, compared with 
animals treated with control chow. Moreover, despite equal inhibition of platelet aggregation, 
ticagrelor prolonged time to arterial occlusion, compared with clopidogrel-treated animals 
(Fig. 6C). In line with our in vitro finding, animals treated with ticagrelor, but not clopidogrel, 
revealed decreased endothelial TF expression in murine CCAs, as compared with rodents 
treated with control chow (Fig. 6D). Instead, plasma TF activity (Fig. 6E) and plasma 
thrombin generation (Fig. 6F) were unchanged between the groups suggesting similar 
plasma coagulation properties. 
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Discussion 
 
Different P2Y12 receptor antagonists have been shown to differentially affect cardiovascular 
outcome in several clinical trials3,4. Particularly, the Study of Platelet Inhibition and Patient 
Outcomes (PLATO) trial showed superior effects of ticagrelor, compared with clopidogrel, in 
reducing mortality in patients with ACS3. Stronger antiplatelet effects and reversible binding, 
which further allows inhibition of newly formed platelets and micro particles, may partly 
account for the greater efficacy of ticagrelor. Nonetheless, increased platelet inhibition 
achieved by prasugrel, compared with clopidogrel, did not translate into a similar reduction of 
overall mortality suggesting the possible involvement of platelet-independent effects4. In line 
with this, we hypothesized that ticagrelor may prevent endothelial activation with a specific 
effect on arterial thrombus formation and its key player TF; this indeed could provide a 
plausible explanation for the reduction in thrombotic events observed in PLATO.  
Indeed, in TNF-α-stimulated HAECs, we found that ticagrelor, but not CAM, reduced TF 
expression via proteasomal degradation and TF activity without affecting TFPI. Interestingly, 
we found that these effects were mediated independently of both the P2Y12 receptor and the 
adenosine transporter ENT1. To test the physiological relevance of our in vitro findings, we 
induced arterial thrombosis in C57BL/6 mice treated with ticagrelor or clopidogrel. Dosages 
were chosen to mimic human plasma concentrations21 and to induce comparable platelet 
inhibition in both groups and, thus, to exclude platelet-dependent effects. Notably, we found 
that time to arterial occlusion was significantly delayed in ticagrelor-treated mice, compared 
with clopidogrel-treated rodents. In line with our in vitro findings ticagrelor, but not clopidogrel, 
reduced protein expression of endothelial TF in murine arteries. Plasma coagulation 
parameters including thrombin generation and tissue factor activity on the other hand 
remained unchanged, which further supports the hypothesis of local vascular antithrombotic 
mechanisms. 
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The herein reported findings support our hypothesis of pleiotropic effects of ticagrelor on 
endothelial cells and expand previous studies describing P2Y12-independent effects of 
ticagrelor7,8. The inhibitory effect on TF displayed by ticagrelor may be particularly favourable 
in patients at risk of cardiovascular complications, as both activation of platelets and 
activation of the coagulation cascade represent key mechanisms in the initiation and 
propagation of arterial thrombus formation as it occurs in ACS. This notion, may contribute to 
the observed decrease in arterial thrombotic events3.  
Unlike previous observations8,21, the herein reported mechanisms cannot be explained by 
increased adenosine levels following ENT1 inhibition. Although adenosine mimics the effect 
of ticagrelor, we did not observe similar results using the ENT1 inhibitor dipyridamole. 
Additionally, adenosine receptor antagonists could not reverse ticagrelor’s effect; thus, 
implying a different mechanism. Correspondingly, patients receiving ticagrelor or adenosine 
show similar side effects, such as the induction of dyspnea3, and the recent finding of 
increased adenosine levels8 through ENT1 inhibition7, provides evidence to link these 
observations. Nevertheless, potent ENT1 inhibitors such as dipyridamole also increase 
adenosine levels8, but do not induce dyspnea31. Therefore, exclusive ENT1 in addition to 
P2Y12 inhibition may not explain the entire mode of action of ticagrelor and further research is 
needed to determine its exact mechanisms. 
Because of the chemical similarity of ticagrelor and adenosine, direct interactions with 
adenosine receptors appear to be likely and have been investigated by others; however, 
such interactions were considered unlikely to be clinically relevant because of the low affinity 
of ticagrelor7. The P2Y12 receptor belongs to the family of P2 purine and pyrimidine G protein-
coupled receptors and 7 further P2Y receptors have been characterized, some of which are 
expressed in the endothelium32. However, whether ticagrelor shows binding affinity to other 
purine and pyrimidine receptors and whether these receptors are responsible for the 
observed effects on endothelial cells remains to be determined.  
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Here we for the first time provide evidence for endothelium-dependent antithrombotic 
properties, which indicates that ticagrelor can affect the coagulation system in addition to its 
well-known antiplatelet effects. Dual antiplatelet therapy is the standard of care in patients 
suffering from ACS2; however, given the high prevalence of this disease1, there is also a 
great number of patients with comorbidities requiring anticoagulant treatment, such as deep 
vein thrombosis, atrial fibrillation, or mechanical heart valves33. Although anticoagulants in 
combination with dual antiplatelet therapy lower the risk of thrombotic events, 
disproportionately increased bleeding rates have been observed34. While single antiplatelet 
therapy using clopidogrel in combination with anticoagulants reduced the risk of bleedings35, 
such an approach may not be sufficient to sustain the low rate of thrombotic events. Thus, 
further studies are needed to determine the effectiveness and safety of new oral 
anticoagulants in combination with more potent platelet antagonists such as ticagrelor33. 
Because of its dual antithrombotic effects, ticagrelor may be a more appropriate choice than 
clopidogrel in patients with ACS with comorbidities requiring additional antithrombotic 
therapy. Along these lines, ticagrelor showed better efficacy than clopidogrel in the PLATO 
trial3. On the other hand, safety in terms of bleeding may be of particular concern in these 
patients as ticagrelor increased non-procedure-related bleeding rates in the PLATO trial3. 
In conclusion, the pleiotropic effects of ticagrelor on the endothelium may in part explain its 
greater efficacy in reducing thrombotic events in patients with ACS and mortality in clinical 
trials; its antithrombotic properties may be particularly promising in patients requiring 
anticoagulant in addition to antiplatelet therapy. Nonetheless, additional antithrombotic 
properties may increase bleeding risk and special attention may be required in patients at 
high risk. 
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Abbreviations 
 
ACS acute coronary syndrome 
ACTB human β-actin 
ADP adenosine diphosphate 
CAM clopidogrel active metabolite 
CCA common carotid artery 
CT cycle threshold 
ENT1 equilibrative nucleoside transporter 1 
ETP endogenous thrombin potential 
GAPDH glyceraldehyde 3-phosphate dehydrogenase 
HAECs human aortic endothelial cells 
HBMVECs human brain microvascular endothelial cells 
HCMVECs human cardiac microvascular endothelial cells 
MFI mean fluorescence intensity 
PLATO study of platelet inhibition and patient outcomes 
RT-PCR real-time polymerase chain reaction 
TF tissue factor 
TFPI tissue factor pathway inhibitor 
TNF-α tumor necrosis factor-alpha 
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Legends 
 
Figure 1. Effects of ticagrelor and CAM on TF expression and activity in HAECs. TF 
protein expression in ticagrelor-pretreated HAECs (n=8) (A), or CAM-pretreated HAECs 
(n=8) (B) 1 hour before stimulation with TNF-α for 5 hours. (C) TF activity in ticagrelor-
pretreated HAECs 1 hour before TNF-α stimulation for 5 hours. (n=8). TF protein expression 
in HAECs pretreated with the PI3 kinase inhibitor wortmannin (n=6) (D), the p70s6 kinase 
inhibitor rapamycin (n=6) (E) or both (n=8) (F) 1 hour prior to ticagrelor treatment for 1 hour 
and subsequent TNF-α stimulation for 5 hours. *p <0.05 vs TNF-α treatment; †p <0.05 vs 
TNF-α + ticagrelor treatment. CAM = clopidogrel active metabolite; GAPDH = glyceraldehyde 
3-phosphate dehydrogenase; HAECs = human aortic endothelial cells; TF = tissue factor; 
TNF-α = tumor necrosis factor-alpha. 
 
Figure 2. Ticagrelor augmented TF transcription but did not alter mRNA half-life in 
HAECs. (A) TF mRNA levels in HAECS after preincubation with ticagrelor 1 hour before 
TNF-α-stimulation for 3 hours (n=7). (B) TF mRNA stability after treatment with TNF-α (10 
ng/mL) for 1 hour and subsequent simultaneous incubation with actinomycin D (10 µg/mL) 
and ticagrelor (n=4-6) for time points between 0 and 180 minutes. *p <0.05 vs TNF-α 
treatment. Act = actinomycin D; AU = arbitrary unit; HAECs = human aortic endothelial cells; 
TF = tissue factor; Tica = ticagrelor; TNF-α = tumor necrosis factor-alpha. 
 
Figure 3. Ticagrelor reduces TF by proteasomal degradation in HAECs. (A) TF 
expression in HAECs stimulated with TNF-α for 3 hours followed by simultaneous treatment 
with the protein translation inhibitor cycloheximide and ticagrelor for additional 2 hours (n=9). 
(B) TF protein expression in HAECs stimulated with TNF-α-for 3 hours and treated with the 
proteasome inhibitor MG-132 and ticagrelor simultaneously for additional 2 hours (n=4). *p 
<0.05 vs TNF-α treatment. †p <0.05 vs. TNF-α + cycloheximide treatment. GAPDH = 
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glyceraldehyde 3-phosphate dehydrogenase; TF = tissue factor; TNF-α = tumor necrosis 
factor-alpha. 
 
Figure 4. Presence of P2Y12 receptor in human platelets but not in endothelial cells. 
(A) P2Y12 RNA in human platelets compared with HAECs, HBMVECs and HCMVECs (n=3). 
(B) Protein expression of the P2Y12 receptor in human platelets, compared with HAECs, 
HBMVECs or HCMVECs (n=3). ACTB = human β-actin; GAPDH = glyceraldehyde 3-
phosphate dehydrogenase; HAECs = human aortic endothelial cells; HBMVECs = human 
brain microvascular endothelial cells; HCMVECs = human cardiac microvascular endothelial 
cells. 
 
Figure 5. Effects of adenosine, dipyridamole and adenosine receptor antagonists on 
TF expression. (A) Effects of adenosine on TF protein (n=10) and (B) RNA expression (n=4) 
after pretreatment for 1 hour and subsequent stimulation with TNF-α for 5 and 3 hours, 
respectively. (C) Effects of the ENT1 inhibitor dipyridamole on TF expression in HAECs after 
pretreatment for 1 hour and subsequent stimulation with TNF-α for 5 hours (n=6). (D) 
Pretreatment of HAECs with adenosine receptor antagonists for 1 hour prior to ticagrelor 
treatment for 1 additional hour and subsequent TNF-α stimulation for 5 hours (n=4). *p <0.05 
vs TNF-α treatment. ACTB = human β-actin; ENT1 = equilibrative nucleoside transporter 1; 
GAPDH = glyceraldehyde 3-phosphate dehydrogenase; HAECs = human aortic endothelial 
cells; RA = receptor antagonists; TF = tissue factor; TNF-α = tumor necrosis factor-alpha. 
 
Figure 6. Platelet aggregation, endothelial TF expression, time to arterial occlusion 
and thrombin potential. (A) Platelet aggregation in response to ADP (10 μM) in mice 
treated with control chow, clopidogrel or ticagrelor for 2 weeks. (B) Plasma concentration of 
ticagrelor in mice treated with ticaglrelor 0.15% added to chow. (C) Time to arterial 
thrombosis in mice treated with control chow (n=10), clopidogrel (n=7) or ticagrelor (n=8). (D) 
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Endothelial TF expression in CCAs of mice treated with control chow, clopidogrel or ticagrelor 
(n=5) and representative transverse sections of CCA stained for endothelium (CD31, red, 
scale bar 5 µm) and TF (green, scale bar 5 µm) (E). Plasma TF activity and (F) plasma 
thrombin potential clopidogrel-, ticagrelor- and control chow-treated animals at baseline. *p 
<0.05 vs control; †p <0.05 vs clopidogrel. ADP = adenosine diphosphate; CCA = common 
carotid artery; ETP = endogenous thrombin potential; MFI = mean fluorescence intensity; TF 
= tissue factor.  
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Supplementary files 
 
Supplementary figure 1 
 
 
Supplementary figure 1. Effects of ticagrelor and CAM on TFPI expression in HAECs. 
TFPI expression in TNF-α-stimulated HAECs treated with ticagrelor (n=8) (A) or CAM (n=8) 
(B). CAM = clopidogrel active metabolite; GAPDH = glyceraldehyde 3-phosphate 
dehydrogenase; HAECs = human aortic endothelial cells; TFPI = tissue factor pathway 
inhibitor; TNF-α = tumor necrosis factor-alpha. 
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Abstract 
 
Aims 
Oral anticoagulation is considered standard therapy for stroke prevention in atrial fibrillation 
(AF). Endocardial activation triggers expression of pro-thrombotic mediators including tissue 
factor (TF) and plasminogen activator inhibitor-1 (PAI-1), and contributes to thrombus 
formation in the left atrial appendage (LAA) of AF patients. Recently, pleiotropic effects of 
specific P2Y12 receptor antagonists were demonstrated however, whether these drugs 
possess antithrombotic effects on LAA endocardial cells currently remains unknown. 
 
Methods and results  
LAA were obtained from 14 patients with known AF undergoing elective cardiac surgery 
including LAA removal at the University Hospital Zurich. LAA endocardial cells were isolated 
and pre-incubated with ticagrelor (10-7, 10-6, 10-5M) or clopidogrel active metabolite (CAM) 
(1.5x10-8, 1.5x10-7, 1.5x10-6M) before stimulation with tumour necrosis factor-alpha (TNF-α) 
(10 ng/mL). Finally, TF and PAI-1 expression and activity were analysed. Ticagrelor, unlike 
CAM, concentration-dependently decreased TNF-α-induced TF expression and TF activity in 
LAA endocardial cells. Further, ticagrelor, but not CAM reduced PAI-1 expression and 
enzyme activity in TNF-α-stimulated LAA endocardial cells. In contrast, TF pathway inhibitor 
(TFPI) remained unaffected by both dugs.  
 
Conclusion 
Ticagrelor, but not CAM, reduces expression and activity of TF and PAI-1 in LAA endocardial 
cells isolated from patients with AF, indicating possible local antithrombotic effects. Such 
pleiotropic properties of ticagrelor may contribute to a reduction in thromboembolic 
complications in patients with AF. 
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Abbreviations 
 
AF atrial fibrillation 
CAM clopidogrel active metabolite 
GAPDH glyceraldehyde 3-phosphate dehydrogenase 
LAA left atrial appendage 
PAI-1 plasminogen activator inhibitor-1 
TF tissue factor 
TFPI tissue factor pathway inhibitor 
TNF-α tumour necrosis factor-alpha 
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Introduction 
 
Atrial fibrillation (AF) is a common cardiac arrhythmia affecting approximately 2% of the 
general population in developed countries1. It increases the risk of thromboembolic 
complications such as cardiogenic stroke as well as heart failure and all-cause mortality2. 
Oral anticoagulation is superior to dual or single antiplatelet therapy3 and is considered 
standard therapy to reduce thromboembolic complications and mortality in AF patients2.  
 
AF leads to thrombus formation in the left atrial appendage (LAA) due to a reduction in blood 
flow, endocardial activation and hypercoagulability mediated through cytokines such as 
tumour necrosis factor-alpha (TNF-α)4. We previously demonstrated that TNF-α-activated 
human LAA endocardial cells increase their levels of tissue factor (TF) and plasminogen 
activator inhibitor-1 (PAI-1) expression and activity, which may contribute to a higher 
thrombogenicity in left vs. right atrial appendages5. An increasing body of evidence is 
suggesting pleotropic effects of certain P2Y12 receptor antagonists6,7; indeed, ticagrelor was 
shown to inhibit the adenosine transporter equilibrative nucleoside transporter 16,7 leading to 
increased plasma levels of adenosine8. In the current study, we investigated whether 
ticagrelor or clopidogrel active metabolite (CAM) affect the expression of prothrombotic 
mediators in TNF-α-activated human LAA endocardial cells. 
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Results 
 
Ticagrelor, but not CAM, reduces TF expression and activity  
Ticagrelor concentration-dependently decreased TNF-α-induced TF expression in LAA 
endocardial cells (Fig. 1A). The maximum effect amounted to 40% reduction in TF 
expression as compared to TNF-α stimulated cells. In contrast, CAM did not affect TF 
expression (Fig. 1B). In line with protein expression, ticagrelor, but not CAM, reduced TF 
activity (Fig. 1C). In contrast, endocardial protein expression of TFPI, the physiological 
antagonist of TF, was affected neither by ticagrelor nor CAM (Supplementary figure 1). 
 
Ticagrelor, unlike CAM, decreases PAI-1 expression and activity 
Similar to TF, ticagrelor also reduced PAI-1 expression in TNF-α-stimulated LAA endocardial 
cells (Fig. 1D). The maximum effect observed was a 67% reduction in PAI-1 expression as 
compared to TNF-α stimulated cells. In contrast, no effect on PAI-1 expression was observed 
with CAM (Fig. 1E). Similarly, ticagrelor, but not CAM reduced enzymatic PAI-1 activity in 
LAA endocardial cells (Fig. 1F). 
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Discussion 
 
In this study we demonstrate for the first time that ticagrelor, but not CAM, reduces TNF-α-
induced TF and PAI-1 expression and activity in LAA endocardial cells isolated from patients 
with AF, hinting towards a possible local antithrombotic effect of ticagrelor at the cellular 
level. 
Current treatment strategies for stroke prevention in patients with AF focus on inhibition of 
clot formation through interference with the coagulation cascade using vitamin K antagonists 
or non-vitamin K oral anticoagulants2,9,10. Antiplatelet therapy, even dual anti-platelet therapy 
using aspirin and clopidogrel has been shown to be inferior to oral anticoagulation in stroke 
prevention in AF patients3,11. Newer generation antiplatelet agents such as ticagrelor, 
however, have not been evaluated for this indication. 
Our current findings unravel a putative additional property of ticagrelor via which 
thromboembolic complications may be reduced, i.e. by decreasing local thrombogenicity of 
LAA endocardial cells through the reduction of crucial prothrombotic mediators such as TF 
and PAI-1. An increasing body of evidence suggests pleiotropic effects of ticagrelor6,7; indeed 
it was shown to inhibit the adenosine transporter equilibrative nucleoside transporter 16,7 
thereby leading to increased adenosine plasma concentrations in cardiac patients8. The 
current results indicate the possibility of a local antithrombotic effect of ticagrelor in the LAA 
of AF patients. It currently remains unknown whether other anticoagulant drugs may have 
similar properties. A recent study reported that rivaroxaban, in contrast to dabigatran, 
reduced TF expression in endothelial cells12. However, these experiments were performed in 
human vein endothelial cells (instead of left atrial endocardial cells in our setting) and only 
reported changes in TF gene expression leaving out protein expression as well as enzyme 
activity12. Yet, these findings in congregate raise the possibility that local antithrombotic 
effects may be operative in the reduction of stroke risk observed with anticoagulants.  
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Twenty to 30% of patients with AF suffer from comorbidities such as coronary artery disease 
requiring antiplatelet therapy2,9. Optimal antithrombotic regimen in these patients is currently 
a matter of debate due to the high bleeding risk associated with combined anticoagulant and 
antiplatelet therapy9. While the role of new P2Y12 antagonists such as ticagrelor has not yet 
been addressed9 and is subject of ongoing studies13, local antithrombotic mechanisms by 
ticagrelor in the LAA may be of particular interest (and value) in this specific patient 
population. Further studies are required to investigate whether the observed ex vivo effects of 
ticagrelor translate into improved patient outcome, including both thromboembolic as well as 
bleeding complications.  
 
In summary, our results indicate that ticagrelor reduces the expression and activity of local 
procoagulant proteins in LAA endocardial cells, which may contribute to a reduction of 
thromboembolic complications in patients with AF. Our findings may instigate further 
research investigating the clinical implications of these findings, particularly for patients with 
AF in need of concomitant antiplatelet therapy. 
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Figure and Figure Legend 
 
Figure 1. Effects of ticagrelor and CAM on expression and activity of thrombotic 
mediators in LAA endocardial cells. (A) Western blotting analysis for TF protein 
expression in LAA endocardial cells pretreated with increasing concentrations of ticagrelor 
(n=14), or (B) CAM (n=14) with/without TNF-α. (C) ELISA for TF activity in LAA endocardial 
cells pretreated with ticagrelor or CAM with/without TNF-α stimulation (n=13). (D) Western 
blotting analysis for PAI-1 protein expression in LAA endocardial cells pretreated with 
increasing concentrations of ticagrelor (n=14), or (E) CAM (n=14) with/without TNF-α. (F) 
ELISA for PAI-1 activity in LAA endocardial cells pretreated with ticagrelor or CAM 
with/without TNF-α stimulation (n=13). (G) Schematic representation of main study finding. 
Data are expressed as mean ± SD. One-way ANOVA with Tukey post hoc test or unpaired 
two-tailed Student’s t-test was applied. *p <0.05 vs TNF-α; †p <0.05 vs TNF-α + CAM. CAM 
= clopidogrel active metabolite; ELISA = enzyme-linked immunosorbent assay; GAPDH = 
glyceraldehyde 3-phosphate dehydrogenase; LAA = left atrial appendage; PAI-1 = 
plasminogen activator inhibitor-1; SD = standard deviation; TF = tissue factor; TFPI = tissue 
factor pathway inhibitor, TNF-α = tumour necrosis factor-alpha. 
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Supplementary Material 
 
Material and Methods 
 
Drugs 
Ticagrelor and CAM were provided by AstraZeneca, Mölndal, Sweden and Sanofi-Aventis, 
Germany, respectively. 
 
Study participants 
LAA were obtained from 14 patients with known AF undergoing elective cardiac surgery 
(coronary artery bypass grafting and/or valve surgery, or surgical AF ablation and LAA 
occlusion) including LAA removal at the University Hospital Zurich1. All participants signed an 
informed consent form and the study was approved by the cantonal ethical committee Zurich 
“Kantonale Ethikkommission Zürich”.  
 
Isolation of left atrial appendages 
LAA endocardial cells were isolated as previously described1. The surgical procedure, 
including removal of the LAA, was performed according to standard operating procedures 
and to the discretion of the cardiac surgeon in charge. After amputation, appendages were 
stored in low glucose DMEM medium (Gibco®, Life Technologies, Switzerland) enriched with 
10% fetal bovine serum. 
 
Isolation of human atrial endocardial cells  
Human LAA endocardial cells were isolated as previously described1. Briefly, after removal of 
DMEM medium, LAAs were washed with pre-warmed washing buffer (HBSS [Ca2+- and 
Mg2+-free, with phenol red] enriched with 10 mM HEPES and 0.1% BSA, pH 7.4); the lumen 
was placed in collagenase–dispase solution (0.4%) and incubated for 35 min at 37°C1. 
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Following incubation, cells were collected, cell suspension was centrifuged (5min, 233rcf, 
4°C) and resuspended in 2 mL of medium (DMEM low glucose, 20% fetal bovine serum, 
100μg/mL heparin, 25mM HEPES, pH 7.4, 1 time non-essential amino acids and 1 time 
penicillin-streptomycin) enriched with 20 μL/mL endothelium cell growth factor (Sigma-
Aldrich, Switzerland)1. Finally, cells were seeded on a gelatine-coated dish (0.1% gelatine, 
bovine skin type B [Sigma-Aldrich, Switzerland])1. The herein described isolation procedure 
yielded endocardial cells of 98% purity1. 
 
Cell culture experiments 
LAA endocardial cells were used for experiments between passage 3 and 4. Cells were 
grown to 80% confluence on gelatine-coated six well plates (TPP, Trasadingen, Switzerland) 
and underwent starvation using growth medium containing 0.5% fetal bovine serum for 16 to 
18 hours. Cells were pre-incubated with ticagrelor (10-7, 10-6, 10-5 M) or CAM (1.5x10-8, 
1.5x10-7, 1.5x10-6 M) 1 hour before stimulation with TNF-α (10 ng/mL) (R&D Systems, 
Minneapolis, MN) for 5 hours. Drug concentration ranges were chosen so as to match 
plasma concentrations found in humans2. Drugs were dissolved in dimethyl sulfoxide at 
concentrations (0.1%) known not to affect TF, TF pathway inhibitor (TFPI) or PAI-1 protein 
expression3. Correspondingly, unstimulated control cells and TNF-α-stimulated cells were 
treated with dimethyl sulfoxide (0.1%) to exclude any other vehicle-dependent effects. 
 
Western blotting 
Protein expression was determined by Western blot analysis as previously described1. 
Endocardial cells were incubated with lysis buffer (NaCl 150 mM, EDTA 1 mM, NaF 1 
mM,  DTT 1 mM, aprotinin 10 mg/mL, leupeptin 10 mg/mL, Na3VO4  0.1 mM, PMSF 1 mM, and 
NP-40 0.5%); protein concentration was determined according to the manufacturer’s 
recommendations (Bio-Rad); 20 – 30 µg of protein lysates were separated on a 10% sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis before being transferred  to a 
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polyvinylidene fluoride membrane by semi-dry transfer. Membranes were incubated with 
primary antibodies overnight at 4°C on a shaker. Secondary antibodies were applied for 1 
hour at room temperature. Densitometric analyses were performed and protein expression 
was normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Antibodies 
against TF (ADG4503; 1:2000), TFPI (ADG72; 1:8000) were purchased from American 
Diagnostica; anti-PAI-1 (1:500) from Santa Cruz Biotechnology; anti-GAPDH antibody 
(MAB374; 1:40000) from Merck Millipore. Secondary anti-mouse (1031-05) and anti-rabbit 
(4050-05) antibodies were obtained from SouthernBiotech. 
 
Tissue factor activity assay 
TF activity was determined according to the manufacturer’s recommendations (Sekisui 
Diagnostics, ACTICHROME® TF, 846). Endocardial cells were lysed (50 mmol/L Tris-HCl, 
100 mmol/L NaCl, 0.1% Triton X-100, pH 7.4), diluted 1:15 in assay buffer, and mixed with 
human factor VIIa and X, which leads to conversion of factor X to Xa; factor Xa subsequently 
cleaves the chromogenic substrate SPECTROZYME® FXa. Finally, absorbance was 
measured at 405 nm and after background subtraction, optical density was normalized to 
protein concentration as determined according to the manufacturer’s recommendations (Bio-
Rad). 
 
Plasminogen activator inhibitor-1 activity assay 
PAI-1 activity was determined according to the manufacturer’s recommendations (Sekisui 
Diagnostics, SPECTROLYSE® PAI-1 activity assay). Briefly, 30 μg of protein lysates were 
incubated with tissue plasminogen activator allowing reaction with PAI-1 in the samples. 
Residual tissue plasminogen activator activity was then measured after adding human glu-
plasminogen, poly-D-lysine and a chromogenic substrate for plasmin. Residual tissue 
plasminogen activator catalysed the conversion of plasminogen to plasmin, which 
subsequently hydrolysed the chromogenic substrate. PAI-1 activity is thus inversely 
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proportional to residual tissue plasminogen activator activity. Absorbance was measured at 
405 nm and following background subtraction, optical density was normalized to protein 
concentration as determined according to the manufacturer’s recommendations (Bio-Rad). 
 
Statistical analysis 
Data are expressed as mean ± standard error of the mean. Statistical analysis was 
performed using one-way ANOVA with Tukey post hoc test or unpaired two-tailed Student’s t-
test as appropriate. A probability value ≤0.05 was considered as statistically significant and 
calculated by Prism 6 (GraphPad software). 
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Supplementary Figure and Figure Legend 
 
Supplementary Figure 1 
 
 
 
Supplementary Figure 1. Effects of ticagrelor and CAM on TFPI protein expression in LAA 
endocardial cells. (A) Western blotting analysis for TFPI protein expression in LAA 
endocardial cells pretreated with increasing concentrations of ticagrelor (n=14), or (B) CAM 
(n=14) with/without TNF-α. Data are expressed as mean ± SD. Unpaired two-tailed Student’s 
t-test was applied. *p <0.05 vs TNF-α. CAM = clopidogrel active metabolite; GAPDH = 
glyceraldehyde 3-phosphate dehydrogenase; LAA = left atrial appendage; SD = standard 
deviation; TFPI = tissue factor pathway inhibitor, TNF-α = tumour necrosis factor-alpha. 
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6 Summary 
6.1 Ticagrelor, but not clopidogrel active metabolite, reduces endothelial 
tissue factor via proteasomal degradation 
In our initial study we showed that ticagrelor, unlike CAM, dose-dependently reduced TF 
protein expression as well as TF enzyme activity in TNF-α-stimulated HAECs indicating local 
antithrombotic properties of ticagrelor on the human endothelium1 in addition to its well-
described anti-platelet effects.2 By investigating the underlying molecular mechanisms, we 
found that the reduction in endothelial TF expression by ticagrelor was reversed by 
wortmannin and rapamycin suggesting the involvement of the signalling molecules PI3K and 
p70s6 kinase.1 Furthermore, inhibition of proteasomes using MG-132 reversed the effects of 
ticagrelor on TF expression in HAECs.1  On the other hand, ticagrelor did not decrease TF 
mRNA nor did it affect TF mRNA stability indicating that ticagrelor reduced endothelial TF 
expression by proteasomal degradation rather than mRNA modification.1 Interestingly, the 
observed effects of ticagrelor were mediated independently of the ADP receptor P2Y12,1 the 
target receptor of ticagrelor on platelets3, since it was not expressed in HAECs, neither on 
the mRNA nor on the protein level.1 Recently it was shown that ticagrelor also inhibits the 
adenosine transporter ENT1,4 which mediates cellular uptake of adenosine in red blood cells, 
among others,5 thereby increasing adenosine plasma levels in patients treated with 
ticagrelor.6 These findings led to the hypothesis that ticagrelor may inhibit ENT1, known to be 
expressed in endothelial cells,7 and subsequently increases extracellular adenosine levels, 
which in turn affect TF expression through one of the four endothelial adenosine receptors8. 
In line with previous reports,9 adenosine dose-dependently decreased TF expression in TNF-
α-stimulated HAECs.1 However, adenosine, unlike ticagrelor, exerted its effect via a reduction 
of TF mRNA.1 In contrast to ticagrelor, dipyridamole, a slightly more potent ENT1 inhibitor4, 
did not reduce TF protein expression in HAECs and thus, not mimic the effects of ticagrelor.1 
Lastly, inhibition of all adenosine receptors individually or in combination did not reverse the 
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reduction of TF mediated by ticagrelor thereby disproving the ENT1 hypothesis in endothelial 
cells.1 
 
6.2 Ticagrelor, compared with clopidogrel, decreases endothelial tissue 
factor expression and arterial thrombosis in mice 
Next, we investigated the physiological relevance of our in vitro findings in a mouse model of 
photochemical-induced arterial thrombosis and found that ticagrelor, but not clopidogrel, at 
physiological plasma concentrations, reduced TF expression in the endothelium of common 
carotid arteries.1 Furthermore, ticagrelor prolonged time to arterial occlusion, compared with 
clopidogrel, in mice.1 Plasma TF activity and endogenous thrombin potential, on the other 
hand, were comparable among the treated groups.1 Likewise, platelet aggregation in 
response to ADP was inhibited to similar extents in both mice treated with ticagrelor and 
clopidogrel.1 These findings indicate that ticagrelor exerts more potent antithrombotic 
properties, compared with clopidogrel, which was associated with a local reduction of 
endothelial TF expression and independent of changes in plasma TF activity, systemic 
coagulation or inhibition of ADP-induced platelet aggregation.1  
 
6.3 Ticagrelor, unlike clopidogrel active metabolite, reduces thrombogenicity 
in atrial fibrillation patients 
AF triggers thrombus formation in LAA leading to systemic embolism such as ischemic stroke 
causing substantial morbidity and mortality.10 Although anticoagulant treatment is considered 
standard therapy to prevent thromboembolic complications10, patients with AF frequently 
have comorbidities such as ACS requiring antiplatelet therapy.11 Therefore, we studied 
whether certain P2Y12 receptor antagonist may possess local antithrombotic properties in 
endocardial cells isolated from LAA of AF patients.12 Recently it was shown that the 
thrombotic factors TF and plasminogen activator inhibitor-1 (PAI-1) are expressed to a higher 
extent in left, as compared with right atrial appendages, which may in part explain the greater 
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thrombogenicity observed in LAA.13 In accordance with our previous findings in HAECs and a 
mouse model of arterial thrombosis1 we found that ticagrelor, unlike CAM, reduced TF and 
PAI-1 protein expressions as well as enzyme activities in TNF-α-stimulated LAA endocardial 
cells isolated from AF patients.12 On the other hand we did not observe different expression 
levels of TFPI, the physiological antagonist of TF.12 Indeed, this translational study indicates 
local antithrombotic properties of ticagrelor, which may lower thrombogenicity in AF 
patients.12  
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7 Discussion 
7.1 Ticagrelor exhibits platelet-independent antithrombotic effects on the 
endothelium 
Cardiovascular disease including coronary artery disease and stroke among others is the 
leading cause of death in both men and women in Europe.14 Arterial thrombus formation 
following rupture of an atherosclerotic plaque is the key pathophysiological mechanisms 
leading to an ACS.15 Platelets, in addition to the coagulation system, are crucially involved in 
thrombus formation and inhibition of platelet aggregation has been proven to reduce 
thrombogenesis and thus MI and stroke.16-19 In 1988 the second international study of infarct 
survival (ISIS-2) study showed that platelet inhibition by aspirin reduces non-fatal MI, non-
fatal stroke and vascular mortality, compared with placebo.16 Later, dual antiplatelet therapy 
(DAPT) using the P2Y12 receptor antagonist clopidogrel in addition to aspirin was reported to 
further reduce non-fatal MI, stroke and CV death in the Clopidogrel in Unstable Angina to 
Prevent Recurrent Events (CURE) study.17 In more recent years, however, newer 
generations of P2Y12 receptor antagonists have evolved and were compared with the 
thienopyridine clopidogrel.18,19 Prasugrel is a third generation thienopyridine and like 
clopidogrel requires cytochrome P450 metabolism in order to form its active metabolite, 
which irreversibly binds the platelet ADP receptor P2Y12.2 Yet, prasugrel only requires a one-
step activation, as compared with the two-step activation of clopidogrel20 and platelet 
inhibition occurs faster and to a higher extend; also, inter-individual variability and non-
responsiveness to prasugrel is lower.21,22 Consequently, prasugrel reduced the incidence of 
death from cardiovascular causes, non-fatal MI, or non-fatal stroke in patients with ACS, as 
compared with clopidogrel.19 Nevertheless, prasugrel also increased major bleeding rates 
and thus, overall mortality was comparable in prasugrel- and clopidogrel treated patients.19 In 
contrast, ticagrelor is a cyclopentyl-triazolo-pyrimidine, which does not require cytochrome 
P450 activation and binds the P2Y12 receptor directly and reversibly2. Like prasugrel, 
ticagrelor displays faster and greater inhibition of ADP-induced platelet aggregation23 and 
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inhibits newly formed platelets more efficiently in patients with high platelet turnover24. 
Correspondingly, ticagrelor, compared with clopidogrel, further reduced the incidence of 
death from vascular causes, MI and stroke in ACS patients in the Platelet Inhibition and 
Patient Outcomes (PLATO) study.18 Importantly, major bleedings were not higher and 
ticagrelor reduced overall mortality.18 Despite the fact that both prasugrel and ticagrelor show 
greater platelet inhibition compared with clopidogrel,2 only ticagrelor reduced overall 
mortality18,22. Therefore, we hypothesized that platelet-independent effects of ticagrelor may 
contribute to this observation. 
Indeed, we found that ticagrelor reduced endothelial TF expression and activity by 
proteasomal degradation in HAECs and that ticagrelor decreased endothelial TF expression 
in murine arteries subsequently prolonging time to arterial occlusion in mice, compared with 
clopidogrel.1 Furthermore, ticagrelor lowered TF and PAI-1 expression in endocardial cells 
isolated from LAA of AF patients.12 These results strongly indicate local antithrombotic 
properties of ticagrelor on endothelial and endocardial cells and may in part explain the 
reduced mortality observed in PLATO. 
 
7.2 Ticagrelor-mediated tissue factor reduction in endothelial cells and its 
underlying molecular mechanisms 
We found that ticagrelor, but not CAM, concentration-dependently reduced TF expression as 
well as TF activity in HAECs and subsequently investigated the underlying molecular 
mechanisms.1 We found that the signalling molecules PI3K and p70s6 were involved in the 
reduction of TF protein expression by ticagrelor.1 This observation pointed towards an 
involvement of the P2Y12 receptor, a metabotropic G-protein coupled receptor linked to the 
downstream signalling molecule PI3K in platelets25. Nevertheless, we did not detected P2Y12 
mRNA or protein in endothelial cells.1  
Recently, platelet- as well as P2Y12 receptor-independent pleiotropic effects have been 
described for ticagrelor.26 Unlike thienopyridines, ticagrelor also binds to the adenosine 
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transporter ENT1,4 which is expressed in red blood cells and endothelial cells among 
others.5,7 ENT1 mediates adenosine uptake in red blood cells, which was decreased by 
ticagrelor in vitro27 and correspondingly, higher adenosine plasma levels were found in ACS 
patients after treatment with ticagrelor.6 Adenosine is known to inhibit platelet aggregation28 
and indeed, adenosine contributed to the inhibition platelet aggregation in whole blood 
treated with ticagrelor29. Since both ENT1 and adenosine receptors are expressed in 
endothelial cells7,8, we tested the hypothesis that ticagrelor inhibits ENT1 in HAECS 
increasing extracellular levels of adenosine and subsequently reducing TF via endothelial 
adenosine receptors. Indeed, adenosine decreased endothelial TF expression; however; this 
observation was mediated via a reduction in TF mRNA rather than proteasomal degradation 
as observed with ticagrelor1. Also, the ENT1 inhibitor dipyridamole4 did not mimic, and 
inhibition of adenosine receptors did not reverse the effects of ticagrelor on TF expression 
suggesting that our observations were occurring independently of ENT1.1 Indeed, ticagrelor 
shows side effects similar to adenosine such as dyspnoea18,30,31 and increased adenosine 
levels through inhibition of ENT1 by ticagrelor4 represent a plausible explanation for this 
finding. Nevertheless, several arguments speak against this hypothesis. Firstly, the ENT1 
inhibitor dipyridamole does not cause dyspnoea32,33 and secondly, the adenosine 
triphosphate analogue cangrelor, which, like ticagrelor, inhibits P2Y12 receptors reversibly but 
does not bind to ENT14 also causes dyspnoea, albeit to a lesser extent.34,35 These 
observation further support the concept that ticagrelor may exert additional mechanism 
beyond P2Y12 and ENT1 inhibition.  
Other molecular mechanisms potentially explaining our in vitro findings include direct binding 
of ticagrelor to adenosine receptors due to their molecular similarity. Indeed, ticagrelor shows 
low binding affinity to the adenosine receptors A1, A2a, A2b and A3; however clinical 
concentrations of ticagrelor are of neglectable functional relevance.4 Moreover, ticagrelor 
may exhibit binding affinity to other family members of the P2 purine and pyrimidine 
  99 
receptors expressed in endothelial cells.36 However, to date no such interactions have been 
described. 
 
7.3 Ticagrelor and arterial thrombosis in vivo – relevance of endothelial 
tissue factor 
In C57BL/6 mice we found that ticagrelor reduced arterial thrombosis more effectively than 
clopidogrel and, correspondingly, that ticgrelor-treated mice showed lower endothelial TF 
expression.1 On the other hand, we did not observe differences in platelet aggregation or 
systemic coagulation including plasma TF activity and endogenous thrombin potential 
between the two groups.1 These results suggest that ticagrelor exerts local antithrombotic 
properties by reducing endothelial TF expression in addition to its well-described antiplatelet 
effects.1 
TF plays a crucial role in arterial thrombosis as it initiates the extrinsic coagulation cascade 
by activating factor VII37 followed by factor IX and X38 and subsequently thrombin; thrombin in 
turn, activates a positive feedback loop39 finally leading to large amounts of fibrin formation40 
in addition to platelet activation.41 TF is expressed in the entire vasculature including 
endothelial cells42, VSMC and adventitial cells43 as well as on circulating TF-containing 
microparticles released from endothelial cells44; In pathological conditions, such as high 
shear flow45 as occurring in a stenosed artery and during inflammation as occurring in 
atherosclerosis, TF expression is upregulated.46 Consequently, TF is detected in the necrotic 
core of atherosclerotic plaques.43,47,48 Vascular, rather than blood cell-derived TF appears to 
play a relevant role in arterial thrombus formation.49 Day and colleagues showed that mice 
expressing low amounts of TF in bone marrow cells did not have prolonged arterial occlusion 
times and that mice with TF deficiency that were transplanted with bone marrow cells 
expressing physiologic amounts of TF, did not have reduced arterial occlusion times.49 
Importantly, the group used the same experimental mouse model for arterial thrombosis as 
we did in our study, i.e. photochemical injury of the carotid artery by bengal rose.49 The 
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relevance of TF in arterial thrombosis was further supported by Pawashe et al. showing that 
anti-TF antibody treatment decreased arterial thrombosis in common carotid arteries of 
rabbits50. Lastly, clinical studies found an association of TF with cardiovascular risk factors51-
54 and the incidence of MI.55 
Whether indeed the decrease of endothelial TF expression by ticagrelor entirely explains the 
reduction in arterial thrombosis observed in mice remains to be proven by rescue 
experiments. Since the exact mechanisms leading to TF degradation are not entirely 
understood, it appears difficult to rescue endothelial TF reduction in vivo without affecting 
other sources of TF. On the other hand, one would expect no differences in arterial thrombus 
formation in endothelial-specific TF knockout mice treated with ticagrelor or clopidogrel and 
exposed to photochemical injury of the common carotid arteries. Yet, we did not have access 
to such a mouse strain. 
 
Although we have ruled out other potential and relevant mechanisms explaining the 
differences in arterial thrombus formation between ticagrelor- and clopidogrel-treated 
rodents, such as alterations in platelet aggregation, plasma TF activity and systemic 
coagulation, additional possible explanations remain. Kirby et al. reported that inhibition of 
platelet aggregation by NO, which is usually rather low, increased significantly in the 
presence of the P2Y12 receptor antagonist prasugrel active metabolite or ticagrelor.56 This 
finding was explained by synergistic effects of NO and P2Y12 receptor inhibition on the 
reduction of the downstream signalling molecule PI3K.56 NO is produced in endothelial cells 
by endothelial NO synthase57 and inducible NO synthase during inflammation58. Interestingly, 
we have previously shown that ticagrelor, unlike CAM, dose-dependently increases 
phosphorylation of endothelial NO synthase at the activation side serine 1177.59 In line with 
our findings, treatment with ticagrelor augmented myocardial NO synthase in rats.60 
Increased phosphorylation of endothelial NO synthase may result in higher concentration of 
NO at the vessel wall and may contribute to higher platelet inhibition in vivo. 
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Drug dosages of P2Y12 receptor antagonists in rodents 
In humans, ticagrelor, compared with clopidogrel, exerts greater inhibition of ADP-induced 
platelet aggregation23. Therefore, different effects on MI, stroke and CV death between 
clopidogrel- and ticagrelor-treated patients18,30 may be due to different platelet inhibitory 
effects. To rule out platelet-dependent effects in our study we selected dosages of ticagrelor 
and clopidogrel that resulted in comparable inhibition of ADP-induced platelet aggregation.1 
Importantly, we performed platelet aggregometry in whole blood as it was recently reported 
that adenosine contributes to whole blood platelet inhibition in the presence of ticagrelor.29 In 
order to show that our experiments were performed at minimal drug concentrations and that 
none of the drugs were used at excessively high concentrations, we performed dose 
response experiments and found that reducing drug dosages by only one third resulted in 
residual and comparable platelet reactivity in ticagrelor- and clopidogrel-treated animals.1 
Besides, dosages in our in vitro and in vivo experiments were chosen so as to reflect plasma 
concentration found in humans. Recommended dosages in cardiovascular patients for 
clopidogrel and ticagrelor represent a loading dosage of 300 – 600 mg followed by 75 mg 
once daily and a loading dosage of 180 mg followed by 90 mg twice daily, respectively.11 
Thus, maintenance dosages differ 2.4 fold. Such dosages provide plasma concentration of 
0.16 – 0.18 uM of clopidogrel active metabolite and 1 – 1.5 uM of ticagrelor in humans2. 
Likewise, drug dosages in our study differed 2.5 fold (ticagrelor 0.15% vs. clopidogrel 
0.06%).1 However, unlike in humans,23 these dosages resulted in equivalent platelet 
inhibition in mice1, which was also in line with previous findings in rats.60 In addition, we 
evaluated ticagrelor plasma concentration in mice and found concentrations of 2.7±0.7 uM,1 
which were comparable to humans.2 
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8 Outlook 
Here we report that ticagrelor, unlike CAM, reduces endothelial TF by proteasomal 
degradation in vitro.1 On a molecular level we found that the effect of ticagrelor on TF was 
mediated by the signalling pathways PI3K and p70s6 kinase.1 We have shown that the 
observed effects were independent of the P2Y12 receptor as well as ENT1 indicating that 
other mechanisms may be involved.1 Yet, specific additional target receptors of ticagrelor 
remain to be determined. To assess the physiological relevance of our in vitro data in vivo, 
we showed that ticagrelor, unlike clopidogrel, reduced endothelial TF expression in common 
carotid arteries and prolonged arterial occlusion times in mice; further, we ruled out other 
potential and relevant mechanisms, which could have contributed to this observation 
including platelet aggregation, plasma TF activity and systemic coagulation.1 In order to 
finally prove the relevance of endothelial TF in our experiments, a rescue experiment 
specifically preventing the reduction of endothelial TF by ticagrelor in vivo, without affecting 
other sources of TF, appears essential. 
Our study indicates local antithrombotic effects of ticagrelor at the vessel wall in addition to 
its antiplatelet effects.1 Such properties may have contributed to the reduction of clinical 
events including MI and stroke in ACS patients treated with ticagrelor in clinical trials.18,30 On 
the other hand, dual antithrombotic effects of ticagrelor may contribute to an increased 
bleeding risk. Although ticagrelor did not augment total major bleeding events, fatal 
intracranial bleeds were higher in ACS patients treated with ticagrelor, compared with 
clopidogrel.18 Whether this observation may be due to higher platelet inhibition23 or due to the 
local antithrombotic properties of ticagrelor1 remain speculative.  
 
In a subsequent study we investigated whether the antithrombotic properties displayed by 
ticagrelor12 could also be relevant in AF patients. Previously it was reported that LAA 
endocardial cells express higher levels of procoagulant TF and PAI-1, as compared with right 
atrial appendages, which may contribute to the higher thrombogenicity observed in LAA.13 
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Therefore, we investigated whether ticagrelor or CAM may affect TF or PAI-1 expression in 
LAA endocardial cells isolated from AF patients. Indeed, we found that ticagrelor, but not 
CAM, reduced TF and PAI-1 protein expressions as well as enzyme activities indicating local 
antithrombotic mechanisms in AF patients.12 AF is a common cardiac arrhythmia, which is 
associated with an increased risk of stroke and mortality and oral anticoagulation is the 
treatment of choice to reduce thromboembolic complication.10 Indeed, anticoagulation has 
been shown to be superior to antiplatelet therapy (single or DAPT).61 Yet, newer and more 
potent generations of P2Y12 receptor antagonists including ticagrelor have not been 
compared to oral anticoagulation in AF patients in randomized clinical trials. The described 
local antithrombotic properties of ticagrelor in LAAs of AF patients may be of clinical 
relevance and may affect thrombogenicity in these patients;12 however, this hypothesis 
needs to be addressed in additional clinical studies. 
Frequently, AF patients have comorbidities such as ACS and require both anticoagulant and 
antiplatelet therapy, referred to as triple anticoagulation.11 In such patients, ticagrelor may be 
the preferred choice in order to reduce thromboembolic complications. Triple anticoagulation 
on the other hand increases bleeding complications substantially and choosing the ideal 
treatment to prevent thrombotic events without causing bleedings is challenging.11 In patients 
with an ACS receiving DAPT (aspirin and a thienopyridine), small dosages of oral 
anticoagulants are sufficient to increased bleeding rates significantly.62 Consequently, in 
patients with anticoagulant treatment undergoing percutaneous intervention requiring DAPT, 
single (clopidogrel) versus DAPT reduced bleeding complications significantly;63 however, 
although not statistical significant, higher rates of thrombotic events have been observed in 
the single antiplatelet therapy group.63 Therefore, it remains to be determined whether 
reducing triple antithrombotic therapy to oral anticoagulation and P2Y12 receptor inhibition is 
sufficient to sustain low thrombotic events. The local anti-thrombotic properties of ticagrelor 
appear beneficial in AF patients requiring platelet antagonists due to comorbidities such as 
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ACS; however, further clinical studies are required to prove the effectiveness and safety of 
newer generations of P2Y12 receptor antagonists such as ticagrelor in AF.64   
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9 Abbreviations 
ACS acute coronary syndrome 
ADP adenosine diphosphate  
AF atrial fibrillation 
CAM clopidogrel active metabolite 
CURE Clopidogrel in Unstable Angina to Prevent Recurrent Events 
CV cardiovascular 
CVD cardiovascular disease 
DAPT dual antiplatelet therapy 
eNOS endothelial nitric oxide synthase 
ENT1 equilibrative nucleoside transporter 1 
GP glycoprotein 
H2O2 hydrogen peroxide 
HAECs human aortic endothelial cells 
ISIS-2 second international study of infarct survival 
LAA left atrial appendage 
LDL low-density lipoprotein 
MI myocardial infarction 
NADPH nicotinamide adenine dinucleotide phosphate 
NO nitric oxide 
O2- superoxide anion 
OH hydroxyl radicals 
ONOO- peroxynitrite 
PAI-1 plasminogen activator inhibitor-1 
PGI2 prostacyclin 
PI3K phosphoinositide 3-kinase 
PLATO study of Platelet Inhibition and Patient Outcomes 
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ROS reactive oxygen species 
TF tissue factor 
TFPI tissue factor pathway inhibitor 
TNF-α tumor necrosis factor-alpha 
VCAM-1 vascular cell adhesion molecule-1 
VSMC vascular smooth muscle cells 
vWF von Willebrand factor 
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